RefID PtID PIReceived IsolateYear Country Subtype FirstAA LastAA AASeq Author RefYear MedlineID Journal Title 169 1542 LPV 2010 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQVPIEICGHKAVGTVLIGPTPVNIIGRNLLTQLGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 7995 LPV 2005 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVVEEMSLPGRWKPKMIGGIGGFIKVRQYDQISVEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 8331 LPV 2003 U.S. B 1 99 PQITLWQRPLVTVRVGGQLKEALLDTGADDTVLEEMNLPGTWKPKMIGGIGGFIKVKQYNQIPVEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 8427 LPV 2003 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQVPVEICGHKAIGAVLVGPTPVNIIGRNLLTQIGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 8433 LPV 2002 U.S. B 1 99 PQITLWQRPLVTIKIGGQLMEALLDTGADDTVLEEVNLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGHKVIGTVLVGPTPVNIIGRNLMTQIGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 14155 LPV 2004 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQILIEICGHKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 14229 LPV 2007 U.S. B 1 99 PQITLWQRPLVTIKIGGQIKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQILIEICGHKAIGTVLIGPTPVNIIGRNLLTQIGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 14316 LPV 2007 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEDMSLPGRWKPKMIGGIGGFIKVRQYDQILVEICGHKAIGTVLIGPTPVNIIGRNLLTQIGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 14651 LPV 2006 U.S. B 1 99 PQITLWQRPLVTVKVGGQLKEALLDTGADDTVLEEMSLPGRWKPKMIGGIGGFIKVRQYDQVPIEICGHKATGTVLVGPTPVNIIGRNLLTQIGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 14758 LPV 2008 U.S. B 1 99 PQITLWQRPIVTIKIGGQLKEALLDTGADDTVVEDMALPGRWKPKMIGGIGGFIKVRQYDQIPIEIDGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 16106 LPV 2003 U.S. B 1 99 PQITLWQRPLVSIKVGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQVHIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 16282 LPV 2008 U.S. B 1 99 PQITLWQRPLVTIKIGGQLREALLDTGADDTVLEEMNLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGHKTIGTVLIGPTPVNIIGRNLLTQLGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 16353 LPV 2004 U.S. B 1 99 PQITLWQRPLVTVRIGGELKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 16454 LPV 2007 U.S. B 1 99 PQITLWQRPLVTIKIGGQIKEALLDTGADDTVLEEMNLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGHKAIGTVLIGPTPVNIIGRNLLTQIGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 18321 LPV 2003 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVIEEMNLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGHKTVGTVLIGPTPVNIIGRNLLTQLGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 18363 LPV 2009 U.S. B 1 99 PQITLWQRPIVTIKIGGQLREALLDTGADDTVFEEIDLPGRWKPKMIGGIGGFVKVRQYDQVPIEIYGHRVEGTVLVGPTPANIIGRNLLTQLGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 18380 LPV 2008 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEDMDLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGHKTIGTVLIGPTPVNIIGRNLLTQLGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 18395 LPV 2007 U.S. B 1 99 PQITLWQRPLVTIRIGGQLKEALLDTGADDTVLEDMELPGRWKPKMIGGIGGFIKVRQYDQIPIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 22104 LPV 2006 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEDMNLPGKWKPKMIGGIGGFIKVRQYDQILIEICGYKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 22167 LPV 2007 U.S. B 1 99 PQITLWQRPLVTVKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGHKAIGTVLIGPTPVNIIGRNLLTQIGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 23814 LPV 2006 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEDMNLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGHKAIGTVLIGPTPVNIIGRNLLTQLGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 25043 LPV 2012 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEDMQLPGRWKPKMIGGIGGFIKVKQYDQIPIEICGQKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 25135 LPV 2012 U.S. B 1 99 PQITLWQRPVVTVRIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGHKAVGTVLIGDTPVNIIGRNLLTQIGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 26251 LPV 2006 U.S. B 1 99 PQITLWQRPLVKIKIGGQTKEALLDTGADDTVLEDMNLPGKWKPKMIGGIGGFIKVRQYDQIAIDICGHKAIGTVLVGPTPVNIIGKNLLTQIGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 27909 LPV 2006 U.S. B 1 99 PQITLWQRPLVTVRIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGHKAIGTVLIGPTPVNIIGRNLLTQLGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 30295 LPV 2007 U.S. B 1 99 PQITLWQRPLVVIKIGGQLKEALLDTGADDTVLEEMDLPGKWKPKMIGGIGGFIKVKQYDQVTIEICGHKVVGTVLIGPTPVNIIGRNLLTQLGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 35503 LPV 2009 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEIDLPGRWKPKMIGGIGGFIKVRQYDQVPIEICEHKAVGTVLVGPTPVNIIGRNLLTQIGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 35535 LPV 2006 U.S. B 1 99 PQITLWQRPLVTIKIGGHLKEALLDTGADDTVLEEMNLPGKWKPKMIGGIGGFIKVRQYEQISIEICGHKTIGTVLIGPTPVNIIGRNLLTQIGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 35664 LPV 2007 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQIPLEICGHKAIGTVLIGPTPVNIIGRNLLTQIGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 38039 LPV 2007 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQVPIEICGHKAIGTVLIGPTPVNIIGRNLLTQLGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 41999 LPV 2007 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMALPGRWKPKMIGGIGGFIKVRQYDQITVEICGHKATGTVLVGPTPVNIIGRNLLTQIGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 42036 LPV 2010 U.S. CRF01_AE 1 99 PQITLWQRPIVTIKIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 42598 LPV 2008 U.S. B 1 99 PQITLWQRPLVTIRVGGQLKEALLDTGADDTVLEELHLPGKWKPKMIGGIGGFIKVRQYDQVAVDICGHKAVGTVLVGPTPVNIIGRNLLTQIGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 61598 LPV 2011 U.S. B 1 99 PQITLWQRPLVSIRIGGQLKEALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVRQYDQILVEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 61623 LPV 2009 U.S. B 1 99 PQITLWQRPLVTIKIGGHLKEALLDTGADDTVLEEIDLPGRWKPKMIGGIGGFIKVKQYEEVPIEICGHKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 82168 LPV 2012 U.S. B 1 99 PQITLWQRPLVTIKIEGQLREALLDTGADDTVLEDINLSGRWKPRMIGGIGGFIKVKQYDQVPIEICGHKVTGTVLVGPTPVNIIGRNLMTQLGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 82334 LPV 2011 U.S. B 1 99 PQITLWQRPLVTIKVGGQLKEALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 112894 LPV 2013 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEDMDLPGRWKPKMIGGIGGFIKVRQYEQIPIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 112922 LPV 2013 U.S. B 1 99 PQITLWQRPIVTIKIGGELKEALLDTGADDTVLEEINLTGRWKPKMIGGIGGFIKVRQYDQIPVEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 906 9197 LPV 1998 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKLIGGIGGFIKVREYDQILIEICGHKAIGTVLVGPTPLNIIGRNLLTQIGCTLNF Kempf, DJ 2001 11462018 J Virol Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. 1115 19610 LPV 2003 U.S. B 3 99 LTLWQRPIVTIKIGGQLKEALLDTGADDTVLEDIDLPGKWKPKMIGGIGGFIKVRQYDEISMEICGHKVTGTVLIGPTPVNIIGRNLLTQLGCTLNF PacOaks 2004 Unpublished Sequences from Pacific Oaks. 1115 22707 LPV 2003 U.S. B 4 99 TLWQRPLVTIRIGGQLKEALLDTGADDTVLEEMSLPGRWKPKMIGGIGGFIKVRQYDQVPIEICGQKAIGTVLIGPTPVNIIGRNLLTQIGCTLNF PacOaks 2004 Unpublished Sequences from Pacific Oaks. 1115 22803 LPV 2003 U.S. B 4 99 TLWQRPLVSIKIGGQQKEALLDTGADDTVLEEMSLPGKWKPKMIGGIGGFIKVRQYDQVSIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF PacOaks 2004 Unpublished Sequences from Pacific Oaks. 1115 22870 LPV 2003 U.S. B 4 99 TLWQRPLVRIKIGGQLKEALLDTGADDTVLEDMDLPGRWKPKMIGGIGGFIKVRQYDQILIEICGHRAIGTVLVGPTPVNIIGRNLLTQIGCTLNF PacOaks 2004 Unpublished Sequences from Pacific Oaks. 1115 22901 LPV 2003 U.S. B 4 99 TLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDEILIEICGHKAIGTVLIGPTPVNIIGRNLLTQIGCTLNF PacOaks 2004 Unpublished Sequences from Pacific Oaks. 1115 23191 LPV 2003 U.S. B 4 99 TLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMSLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGHKAIGTVLIGPTPVNIIGRNLLTQLGCTLNF PacOaks 2004 Unpublished Sequences from Pacific Oaks. 1115 23316 LPV 2003 U.S. B 4 99 TLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKIIGGIGGFIKVRQYDQVHIEICGHKAIGTVLIGPTPVNIIGRNLLTKIGCTLNF PacOaks 2004 Unpublished Sequences from Pacific Oaks. 1115 23365 LPV 2004 U.S. B 4 99 TLWQRPLVTIKIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQIPIEISGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF PacOaks 2004 Unpublished Sequences from Pacific Oaks. 1125 20511 LPV 2002 France B 1 99 PQITLWQRPLVTVKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Montes, B 2004 15097148 JAIDS Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B. 1151 21685 LPV 2003 U.S. B 1 99 PQITLWQRPLVSVKVGGQIKEALLDTGADDTILEEMNLPGRWKPKIAGGIGGFIKVRQYDNILIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Friend, J 2004 15353986 AIDS Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen. 1167 6814 LPV 2001 U.S. B 1 99 PQITLWQRPLVTIKIGGQQTEALLDTGADDTVLEEMNLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGHKAIGTVLIGPTPVNIIGRNLLTQLGCTLNF Rhee, SY 2005 15995959 J Infect Dis HIV-1 protease and reverse transcriptase mutations: Correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. 1167 14227 LPV 2002 U.S. B 1 99 PQITLWQRPLVTVKIGGQLKEALLDTGADDTVFEEMSLSGRWKPKMIGGIGGFIKVRQYDQIAIEICGHKAVGTVLIGPTPVNIIGRNMLTQIGCTLNF Rhee, SY 2005 15995959 J Infect Dis HIV-1 protease and reverse transcriptase mutations: Correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. 1167 14379 LPV 2003 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVVEEMALPGRWKPKMIGGIGGFIKVKQYDQIPVEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Rhee, SY 2005 15995959 J Infect Dis HIV-1 protease and reverse transcriptase mutations: Correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. 1167 21094 LPV 2003 U.S. B 1 99 PQITLWQRPLVIIKVGGQLKEALLDTGADDTVLEDMDLPGRWKPKMIGGIGGFIKVRQYDQVPIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Rhee, SY 2005 15995959 J Infect Dis HIV-1 protease and reverse transcriptase mutations: Correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. 1181 12218 LPV 2002 U.K. C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25345 LPV 2004 Portugal G 1 99 PQITLWQRPIVTVKIGGQLIEALIDTGADDTVLEDINLPGKWKPKIIGGIGGFVKVREYDQIPIEICGKKAIGTVVVGPTPINIIGRNMLTQIGCTLNF Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25410 LPV 2003 Portugal G 1 99 PQITLWQRPLVAVRVGGQLIEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPINIIGRNMLTQIGCTLNF Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25461 LPV 2003 Portugal G 1 99 PQITLWQRPLVTVRVGGQLIEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPINIIGRNMLTQIGCTLNF Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25478 LPV 2003 Portugal F 1 99 PQITLWQRPLVTIKVGEQLREALLDTGADDTVLEDINLPGRWKPKMIGGIGGFIKVKQYDHITIEICGHKATGTVLVGPTPVNIIGRNMLTQIGCTLNF Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25512 LPV 2004 Portugal G 1 99 PQITLWQRPLIAVRIGGQLIEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPINIIGRNMLTQIGCTLNF Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25523 LPV 2004 Portugal G 1 99 PQITLWQRPLVTVRIGGQLIEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPINIIGRNMLTQIGCTLNF Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1242 26193 LPV 2003 Spain B 4 99 TLWQRPLVSIKVGGQTKEALLDTGADDTVLEDMKLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Garcia-Bujalance, S 2005 16081972 J Clin Microbiol Comparison between sequence analysis and a line probe assay for testing genotypic resistance of human immunodeficiency virus type 1 to antiretroviral drugs. 1466 67031 LPV 2002 Brazil B 1 99 PQITLWQRPIVTIKVGGQIREALLDTGADDTVLEEIDLPGRWKPRMIGGIGGFVKVKQYDQIPIEICGHKVIGTVLVGPTPTNIVGRNMMTQLGCTLNF Santos, AF 2006 17053347 AIDS Characterization of a new circulating recombinant form comprising HIV-1 subtypes C and B in southern Brazil. 1480 31846 LPV 2004 Malaysia B 1 95 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGKWKPKLIGGIGGFVKVRQYEQIPIEICGHKVIGTVLIGPTPANIIGRNLMTQLGC Tee, KK 2006 16404607 Med Microbiol Immunol Prevalence and pattern of drug resistance mutations among antiretroviral-treated HIV-1 patients with suboptimal virological response in Malaysia. 1480 31854 LPV 2004 Malaysia CRF01_AE 1 95 PQITLWQRPLVTVKIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGC Tee, KK 2006 16404607 Med Microbiol Immunol Prevalence and pattern of drug resistance mutations among antiretroviral-treated HIV-1 patients with suboptimal virological response in Malaysia. 1480 31856 LPV 2004 Malaysia A 1 95 PQITLWQRPIVTVKIGGHLKEVLLDTGADDTVIEDIDLPGRWKPKMIGGIGGFVKVRQYDQILIEICGKKVIGTVLVGPTPFNIIGRNVLTQMGC Tee, KK 2006 16404607 Med Microbiol Immunol Prevalence and pattern of drug resistance mutations among antiretroviral-treated HIV-1 patients with suboptimal virological response in Malaysia. 1592 41549 LPV 2004 Brazil B 6 99 WQRPLVTVKIGDQLKEALLDTGADDTVLEDMNLPGRWKPKMIGGIGGFIKVKQYEQIPIEICGHKVVGTVLVGPTPVNIIGRNLLTQLGCTLNF Eyer-Silva, WA 2007 17992366 Mem Ins Oswaldo Cruz Autochthonous horizontal transmission of a CRF02_AG strain revealed by a human immunodeficiency virus type 1 diversity survey in a small city in inner state of Rio de Janeiro, Southeast Brazil. 1592 41555 LPV 2004 Brazil F 6 99 WQRPLVTIKVGGQLKEALLDTGADDTVLEDIDLPGKWKPKMIGGIGGFIKVKQYDNIVMEICGHKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Eyer-Silva, WA 2007 17992366 Mem Ins Oswaldo Cruz Autochthonous horizontal transmission of a CRF02_AG strain revealed by a human immunodeficiency virus type 1 diversity survey in a small city in inner state of Rio de Janeiro, Southeast Brazil. 1592 41582 LPV 2004 Brazil B 6 99 WQRPIVTVKIGGQLKEALLDTGADDTVFEEMNLPGRWKPKMIGGIGGFIKVRQYDQIIIEICGHKAIGTVLIGPTPVNIIGRNMLTQIGCTLNF Eyer-Silva, WA 2007 17992366 Mem Ins Oswaldo Cruz Autochthonous horizontal transmission of a CRF02_AG strain revealed by a human immunodeficiency virus type 1 diversity survey in a small city in inner state of Rio de Janeiro, Southeast Brazil. 1592 41591 LPV 2006 Brazil B 6 99 WQRPLVTIKIGGQLKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEEVLVEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Eyer-Silva, WA 2007 17992366 Mem Ins Oswaldo Cruz Autochthonous horizontal transmission of a CRF02_AG strain revealed by a human immunodeficiency virus type 1 diversity survey in a small city in inner state of Rio de Janeiro, Southeast Brazil. 1592 41605 LPV 2004 Brazil B 5 99 LWQRPLVTIRIGEQLKEALLDTGADDTVLEEMSLPGRWKPKMIGGIGGFIKVRQYDQICIEICGHKAIGTVLIGPTPVNIIGRNFLTQLGCTLNF Eyer-Silva, WA 2007 17992366 Mem Ins Oswaldo Cruz Autochthonous horizontal transmission of a CRF02_AG strain revealed by a human immunodeficiency virus type 1 diversity survey in a small city in inner state of Rio de Janeiro, Southeast Brazil. 1592 41620 LPV 2005 Brazil B 5 99 LWQRPLVTIKIGGQLKEALLDTGADDTVIEEMTLPGRWKPRMIGGIGGFIKVRQYDQIPVEICGHKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Eyer-Silva, WA 2007 17992366 Mem Ins Oswaldo Cruz Autochthonous horizontal transmission of a CRF02_AG strain revealed by a human immunodeficiency virus type 1 diversity survey in a small city in inner state of Rio de Janeiro, Southeast Brazil. 1603 43154 LPV 2005 South Africa C 4 99 TLWQRPLVSIKVGGQTREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAMGSVLVGPTPVNIIGRNMLTQLGCTLNF Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43165 LPV 2006 South Africa C 4 99 TLWQRPLVTIKVGGQVKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDEILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43167 LPV 2006 South Africa C 4 99 TLWQRPLVTIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQITIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43169 LPV 2006 South Africa C 4 99 TLWQRPLVTIKIAGQVKEALLDTGADDTVFEDINLPGKWKPKMIGGIGGFVKVRQYDQVPIEICGKKAIGSVLVGPTPANIIGRNMLTQLGCTLNF Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43181 LPV 2006 South Africa C 4 99 TLWQRPLVSIKVGGQIREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPANIIGRNMLTQLGCTLNF Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43187 LPV 2006 South Africa C 4 99 TLWQRPLVSIKVGGQTKEALLDTGADDTVLEDINLPGKWKPRMIGGIGGFIKVRQYEQVPIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1629 45880 LPV 2001 Spain K 1 99 PQITLWQRPLVTVRIGGQLIEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQIHIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Holguin, A 2008 18205216 J Med Virol Genetic characterization of complex inter-recombinant HIV-1 strains circulating in Spain and reliability of distinct rapid subtyping tools. 1646 56222 LPV 2006 Unknown B 1 99 PQITLWQRPLVTVKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGHKVIGTVLIGPTPVNIIGRNLLTQLGCTLNF De Meyer, S 2009 19474650 AIDS Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. 1646 56226 LPV 2006 Unknown B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVRQYDQIPLEICGHKAIGTVLIGPTPVNIIGRNLLTQIGCTLNF De Meyer, S 2009 19474650 AIDS Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. 1646 56229 LPV 2006 Unknown B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF De Meyer, S 2009 19474650 AIDS Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. 1646 56232 LPV 2006 Unknown B 1 99 PQITLWQRPLVTIKIEGQLREALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF De Meyer, S 2009 19474650 AIDS Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. 1646 56233 LPV 2006 Unknown B 1 99 PQITLWQRPLVTVKIGGQLKEALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF De Meyer, S 2009 19474650 AIDS Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. 1646 56235 LPV 2006 Unknown B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQILVEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF De Meyer, S 2009 19474650 AIDS Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. 1646 56239 LPV 2006 Unknown B 1 99 PQITLWQRPIVTVKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGHKAIGTVLIGPTPVNIIGRNLLTQIGCTLNF De Meyer, S 2009 19474650 AIDS Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. 1646 56242 LPV 2006 Unknown B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVIEEMNLPGRWKPKMIGGIGGFIKVRQYDQVPIEICGHKTIGTVLIGPTPVNIIGRNLLTQLGCTLNF De Meyer, S 2009 19474650 AIDS Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. 1646 56243 LPV 2006 Unknown B 1 99 PQITLWQRPVVTIKIEGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQIPMEICGHKVIGTVLIGPTPVNIIGRNLLTQLGCTLNF De Meyer, S 2009 19474650 AIDS Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. 1651 14870 LPV 2002 South Africa C 1 99 PQITLWQRPLVSIKVGGEIREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Pillay, V 2008 19000027 ARHR HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. 1655 56506 LPV 2001 Thailand CRF01_AE 1 99 PQITLWQRPIVTVKIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGSVLVGPTPVNIIGRNMMTQIGCTLNF Nukoolkarn, S 2004 15650431 ARHR Sequence variability of the HIV type 1 protease gene in Thai patients experienced with antiretroviral therapy. 1676 58819 LPV 2006 Russia A 1 99 PQITLWQRPIVTVRIGGQLKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Thomson, MM 2009 19363451 JAIDS Molecular epidemiology of HIV-1 in St Petersburg, Russia: Predominance of subtype A, former Soviet Union variant, and identification of intrasubtype subclusters. 1676 58837 LPV 2006 Russia A 1 99 PQITLWQRPLVTIRIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Thomson, MM 2009 19363451 JAIDS Molecular epidemiology of HIV-1 in St Petersburg, Russia: Predominance of subtype A, former Soviet Union variant, and identification of intrasubtype subclusters. 1676 58843 LPV 2006 Russia B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVVEEMYLPGRWKPKMIGGIGGFIKVRQYDQVPLEICGQKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Thomson, MM 2009 19363451 JAIDS Molecular epidemiology of HIV-1 in St Petersburg, Russia: Predominance of subtype A, former Soviet Union variant, and identification of intrasubtype subclusters. 1683 4340 LPV 2006 U.S. B 1 99 PQITLWQRPVVTIRVGGQIKEALLDTGADDTVLEEMDLPGRWKPKMIGGIGGFIKVRQYDQISIDICGHKATGTVLIGPTPVNIIGRNLLTQLGCTLNF Rhee, SY 2009 19552527 J Infect Dis Predictive value of HIV-1 genotypic resistance test interpretation algorithms. 1683 16387 LPV 2004 U.S. B 1 99 PQITLWQRPIVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQVHIEICGHKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Rhee, SY 2009 19552527 J Infect Dis Predictive value of HIV-1 genotypic resistance test interpretation algorithms. 1683 17695 LPV 2003 U.S. B 1 99 PQITLWQRPLVTIKVGGQLKEALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVRQYDQILIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Rhee, SY 2009 19552527 J Infect Dis Predictive value of HIV-1 genotypic resistance test interpretation algorithms. 1705 66667 LPV 2004 Brazil F 1 99 PQITLWQRPLVKIKVGGQLKEALLDTGADDTVLEDIDLPGKWKPKMIGGIGGFIKVKQYEDVLIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Dumans, AT 2009 18992847 Infect Genet Evol Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virological failure. 1711 63932 LPV 2006 Congo-Brazzaville CRF01_AE 1 99 PQITLWQRPVVIVKVEGQLKEALLDTGADDTVLEDINLPGKWKPRMIGGIGGFIKVRQYDQITIEICGKKAVGTVLVGPTPVNIIGRNMLTQIGCTLNF Rosen-Zvi, M 2008 18586740 Bioinformatics Selecting anti-HIV therapies based on a variety of genomic and clinical factors. 1711 63939 LPV 2007 Cameroon CRF02_AG 1 99 PQITLWQRPLVTVRIGGQLIEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Rosen-Zvi, M 2008 18586740 Bioinformatics Selecting anti-HIV therapies based on a variety of genomic and clinical factors. 1711 63965 LPV 2009 Congo-Brazzaville C 1 99 PQITLWQRPLVTIKVGGELREALLDTGADDTVLEDINLPGKWKPIMIGGIGGFVKVRQYEQVVIEICGKKAIGTVLVGPTPANIIGRNMLTQLGCTLNF Rosen-Zvi, M 2008 18586740 Bioinformatics Selecting anti-HIV therapies based on a variety of genomic and clinical factors. 1711 63976 LPV 2007 Thailand CRF01_AE 1 99 PQITLWQRPLVTVKVGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Rosen-Zvi, M 2008 18586740 Bioinformatics Selecting anti-HIV therapies based on a variety of genomic and clinical factors. 1736 67338 LPV 2006 Netherlands B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEDMNLPGKWKPKIIGGIGGFVKVRQYDQILIEICGHKAIGTVVVGPTPANIIGRNLLTQIGCTLNF Nijhuis, M 2009 19627247 J Infect Dis Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V. 1736 67339 LPV 2006 Netherlands K 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVFEDMNLPGRWKPKIIGGIGGFIKVREYDHIVIEICGHKAIGTVVVGPTPANIIGRNLLTQIGCTLNF Nijhuis, M 2009 19627247 J Infect Dis Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V. 1736 67340 LPV 2006 Netherlands B 1 99 PQITLWQRPLVTVKIGGQLKEALLDTGADDTVLEEMDLPGRWKPKIIGGIGGFIKVRQYDRILIEICGHKAIGTVVVGPTPVNIIGRNLLTEIGCTLNF Nijhuis, M 2009 19627247 J Infect Dis Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V. 1758 70803 LPV 2006 Germany CRF02_AG 1 99 PQITLWQRPVVKVRIEGQIIEALLDTGADDTVLEEINLPGKWKPKIIGGIGGFIKVRQYDQILIEICGKKAIGTVVVGPTPVNIIGRNMLTQIGCTLNF Knops, E 2010 20139751 AIDS The evolution of protease mutation 76V is associated with protease mutation 46I and gag mutation 431V. 1758 70817 LPV 2005 Germany B 1 99 PQITLWQRPLVPVRIEGQLTEALLDTGADDTVLEDMNLPGRWKPKIIGGIGGFIKVRQYDQIAVDICGHKAIGTVVVGPTPVNIIGRNLLTQIGCTLNF Knops, E 2010 20139751 AIDS The evolution of protease mutation 76V is associated with protease mutation 46I and gag mutation 431V. 1785 73861 LPV 2006 Russia G 1 99 PQITLWQRPVVTAKIGGQLMEVLLDTGADDTVLEDINLPGKWKPKIIGGIGGFVKVREYDQVPIEICGKKAIGTVVVGPTPMNIIGRNILSQIGCTLNL Knops, E 2010 20430786 J Antimicrob Chemother Evolution of protease inhibitor resistance in the gag and pol genes of HIV subtype G isolates. 1785 73873 LPV 2006 Russia G 1 99 PQITLWQRPVISVKVGGQPIEALLDTGADDTVLENINLPGKWKPVIIGGVGGLVKVRQYDHILVEIYDKKVIGTVLVGPTPMNIIGRNILTQIGCTLNF Knops, E 2010 20430786 J Antimicrob Chemother Evolution of protease inhibitor resistance in the gag and pol genes of HIV subtype G isolates. 1815 76044 LPV 2006 Kenya A 1 99 PQITLWQRPLVTVKIEGQLREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDHITIEICEKRAIGTVLVGPTPINIIGRNMLVQLGCTLNF Steegen, K 2009 19531211 AIDS Res Ther Effectiveness of antiretroviral therapy and development of drug resistance in HIV-1 infected patients in Mombasa, Kenya. 1815 76057 LPV 2006 Kenya A 1 99 PQITLWQRPLVTVKIGGQLKEALLDTGADDTVLEDINLQGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Steegen, K 2009 19531211 AIDS Res Ther Effectiveness of antiretroviral therapy and development of drug resistance in HIV-1 infected patients in Mombasa, Kenya. 1824 76383 LPV 2008 Brazil B 1 99 PQITLWQRPLVTIKIGGQTKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVKQYDQIPIEICGHKAIGTVLVGPTPVNIIGRNLMTQIGCTFTF Rodrigues, R 2010 20334570 ARHR Young pregnant women living with HIV/AIDS in Criciuma, southern Brazil, are infected almost exclusively with HIV type 1 clade C. 1824 76384 LPV 2008 Brazil C 1 99 PQITLWQRPLVTIRVGGQLKEALLDTGADDTVLEEMKLPGNWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Rodrigues, R 2010 20334570 ARHR Young pregnant women living with HIV/AIDS in Criciuma, southern Brazil, are infected almost exclusively with HIV type 1 clade C. 1824 76385 LPV 2008 Brazil C 1 99 PQITLWQRPLVTIKVGGQLKEALLDTGADDTVLEEMKLPGNWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Rodrigues, R 2010 20334570 ARHR Young pregnant women living with HIV/AIDS in Criciuma, southern Brazil, are infected almost exclusively with HIV type 1 clade C. 1824 76386 LPV 2007 Brazil C 1 99 PQITLWQRPLVTIRVGGQLKEALLDTGADDTVLEEMKLPGNWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Rodrigues, R 2010 20334570 ARHR Young pregnant women living with HIV/AIDS in Criciuma, southern Brazil, are infected almost exclusively with HIV type 1 clade C. 1824 76387 LPV 2007 Brazil C 1 99 PQITLWQRPLVSIKVGGQTKEALLDTGADDTVLEEIKLPGNWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Rodrigues, R 2010 20334570 ARHR Young pregnant women living with HIV/AIDS in Criciuma, southern Brazil, are infected almost exclusively with HIV type 1 clade C. 1824 76388 LPV 2007 Brazil C 1 99 PQITLWQRPLVTIKVGGQLKEALLDTGADDTVLEEMKLPGIWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGAVLVGPTPVNIIGRNMLTQLGCTLNF Rodrigues, R 2010 20334570 ARHR Young pregnant women living with HIV/AIDS in Criciuma, southern Brazil, are infected almost exclusively with HIV type 1 clade C. 1824 76389 LPV 2007 Brazil C 1 99 PQITLWQRPLVTIRVGGQLKEALLDTGADDTVLEEIKLPGNWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNILTQLGCTLNF Rodrigues, R 2010 20334570 ARHR Young pregnant women living with HIV/AIDS in Criciuma, southern Brazil, are infected almost exclusively with HIV type 1 clade C. 1824 76390 LPV 2007 Brazil C 1 99 PQITLWQRPVVSIKVGGQLREALLDTGADDTVLEDIKLPGNWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Rodrigues, R 2010 20334570 ARHR Young pregnant women living with HIV/AIDS in Criciuma, southern Brazil, are infected almost exclusively with HIV type 1 clade C. 1824 76391 LPV 2007 Brazil C 1 99 PQITLWQRPLVSIRVGGQTKEALLDTGADDTVLEEIKLPGNWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Rodrigues, R 2010 20334570 ARHR Young pregnant women living with HIV/AIDS in Criciuma, southern Brazil, are infected almost exclusively with HIV type 1 clade C. 1824 76394 LPV 2007 Brazil C 1 99 PQITLWQRPLVTIKVGGQLKEALLDTGADDTVLEEMKLPGNWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Rodrigues, R 2010 20334570 ARHR Young pregnant women living with HIV/AIDS in Criciuma, southern Brazil, are infected almost exclusively with HIV type 1 clade C. 1824 76405 LPV 2007 Brazil C 1 99 PQITLWQRPLVTIKVGGQIKEALLDTGADDTVLEEIKLPGNWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGGTLNF Rodrigues, R 2010 20334570 ARHR Young pregnant women living with HIV/AIDS in Criciuma, southern Brazil, are infected almost exclusively with HIV type 1 clade C. 1824 76406 LPV 2007 Brazil C 1 99 PQITLWQRPLVPIKVGGQQKEALLDTGADDTVLEDIKLPGNWKPKMIGGIGGFIKVRQYDQIIIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Rodrigues, R 2010 20334570 ARHR Young pregnant women living with HIV/AIDS in Criciuma, southern Brazil, are infected almost exclusively with HIV type 1 clade C. 1824 76407 LPV 2007 Brazil C 1 99 PQITLWQRPLVTIKVGGLLKEALLDTGADDTVLEELKLPGNWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Rodrigues, R 2010 20334570 ARHR Young pregnant women living with HIV/AIDS in Criciuma, southern Brazil, are infected almost exclusively with HIV type 1 clade C. 1824 76408 LPV 2007 Brazil C 1 99 PQITLWQRPLVTIKIGGQLREALLDTGADDTVLEEIKLPGNWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Rodrigues, R 2010 20334570 ARHR Young pregnant women living with HIV/AIDS in Criciuma, southern Brazil, are infected almost exclusively with HIV type 1 clade C. 1824 76410 LPV 2007 Brazil C 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMKLPGNWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Rodrigues, R 2010 20334570 ARHR Young pregnant women living with HIV/AIDS in Criciuma, southern Brazil, are infected almost exclusively with HIV type 1 clade C. 1824 76419 LPV 2008 Brazil C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEIKLPGNWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Rodrigues, R 2010 20334570 ARHR Young pregnant women living with HIV/AIDS in Criciuma, southern Brazil, are infected almost exclusively with HIV type 1 clade C. 1824 76422 LPV 2007 Brazil C 1 97 PQITLWQRPLVTIRVGGQIKEALLDTGADDTVLEDIKLPGNWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTL Rodrigues, R 2010 20334570 ARHR Young pregnant women living with HIV/AIDS in Criciuma, southern Brazil, are infected almost exclusively with HIV type 1 clade C. 1835 76876 LPV 2007 Brazil B 1 99 PQITLWQRPLVTIRVGEQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGHKAVGTVLVGPTPVNIIGRNLLTQIGCTLNF Ferreira, FG 2010 20156105 ARHR Prevalence of primary drug resistance-associated mutations among HIV type 1 vertically infected children in Belo Horizonte, Brazil. 1908 81702 LPV 2002 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMDLPGKWKPKMIGGIGGFIKVRQYDQVPIEICGHKAIGTVLIGPTPVNIIGRNLLTQLGCTLNF Gulick, RM 2004 15115831 N Engl J Med Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. 1908 81855 LPV 2003 U.S. B 1 99 PQITLWQRPIVTVKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQVPIEIWGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Gulick, RM 2004 15115831 N Engl J Med Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. 1913 83574 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQTREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAVGTVLVGPTPVNIIGRNMLTQLGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83576 LPV 2008 South Africa C 1 99 PQITLWQRPVVTIKVGGQVREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83577 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQVKEALLDTGADDTVLEDINLPGKWKPRMIGGIGGFIKVRQYDQITIEICGKKAIGSVLVGPTPINIIGRNMLTQLGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83578 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83582 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVAGQIKEALLDTGADDTVLEEIDLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83584 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEELSLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGKQAIGTVLVGPTPVNIIGRNMLTQLGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83585 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQTKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83592 LPV 2008 South Africa C 1 99 PQITLWQRPLVTIKVGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVKQYDQILIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83593 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEMKLPGNWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGAVLVGPTPVNIIGRNMLTQLGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83594 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83595 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKIGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83596 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVKQYEEIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83597 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKIGGQIKEALLDTGADDTVLEEINLPGKWRPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83598 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEEILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83600 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQTKEALLDTGADDTVLEEISLPGKWKPKMIGGIGGFIKVRQYDEIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83602 LPV 2008 South Africa C 1 99 PQITLWQRPLVTIKVGGQIREALLDTGADDTVLEDMALTGKWKPKMIGGIGGFIKVRQYEQIPIEICGKKAIGTVLIGPTPVNIIGRNMLTQIGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83603 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVREYEQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83605 LPV 2008 South Africa C 1 99 PQITLWQRPLVTIKVGGQIKEALLDTGADDTVLEEISLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83606 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLEDIDLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83607 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQVLIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83609 LPV 2008 South Africa C 1 99 PQITLWQRPLVTIRVGGQIKEALLDTGADDTVLEEIDLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83610 LPV 2008 South Africa D 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIAIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83611 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEEIPIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83613 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEMSLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLIGPTPINIIGRNLLTQLGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83614 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83615 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKIGGQIKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83617 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83620 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQTKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83622 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQVKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQISIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83623 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQVKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83624 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQMREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83625 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEMNLPGKWKPKMIGGIGGFIKVRQYDQIQIEICGKKAIGAVLIGPTPVNIIGRNMLTQLGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83627 LPV 2008 South Africa C 1 99 PQITLWQRPLVAIKVGGQIREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYEEIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1919 82906 LPV 2003 Spain B 1 99 PQITLWQRPLVAVKIGGQTKEALLDTGADDTVLEEMNLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGHKAVGTVLVGPTPVNIIGRNLLTQIGCTLNF Blanco, JL 2010 Unpublished BarcelonaDB. 1919 82923 LPV 2009 Spain B 4 99 TLWQRPVVAIRIGGQLKEALLDTGADDTVLEEMELPGRWKPKMIGGIGGFIKVRQYDQIPIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Blanco, JL 2010 Unpublished BarcelonaDB. 1919 83010 LPV 2003 Spain B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEDMNLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Blanco, JL 2010 Unpublished BarcelonaDB. 1922 83052 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Wallis, CL 2010 20890651 Virus Genes Case report of the rare deletion at codon 69 of reverse transcriptase in a South African HIV-1 subtype C infected patient. 1939 84370 LPV 2004 U.S. B 1 99 PQITLWQRPVVTIKVGGQLKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILVEICGHRAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84373 LPV 2003 U.S. B 1 99 PQITLWQRPLVTVKVGGQIKEALLDTGADDTVLEEMSLPGRWKPKMIGGIGGFIKVRQYDQITIEICGRTAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84376 LPV 2003 U.S. B 1 99 PQITLWQRPLVTIKIGGQVKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQISIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84378 LPV 2003 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEELSLPGKWKPKMIGGIGGFIKVRQYDQVHVEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84380 LPV 2003 U.S. B 1 99 PQITLWQRPLVTVKIGGQIKEALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVRQYDQVPIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84386 LPV 2003 U.S. C 1 99 PQITFWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84388 LPV 2003 U.S. B 1 99 PQITLWQRPLVTVKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQIPVDICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84389 LPV 2003 U.S. B 1 99 PQITLWQRPLVTIKIGGQVKEALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVRQYDQILIEICGHKAIGTVLIGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84390 LPV 2003 U.S. B 1 99 PQITLWQRPLVTIRIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQISIEICGHKAIGTVLIGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84394 LPV 2003 U.S. B 1 99 PQITLWQRPLVTIKVGGQLKEALLDTGADDTVLEEMTLPGKWKPKMIGGIGGFIKVRQYDQILIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84398 LPV 2005 U.S. D 1 99 PQITLWQRPLVTIRVGGQLKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQITIDICGHKATGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84400 LPV 2004 U.S. B 1 99 PQITLWQRPLVTIKVGGQLKEALLDTGADDTVLEDINLPGRWKPKMIGGIGGFIKVRQYDQILVEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84402 LPV 2003 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWRPKMIGGIGGFIKVRQYDQVPIEICGHKAIGTVLIGPTPVNIIGRNLLTQLGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84403 LPV 2004 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFFKVRQYDQIHIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84407 LPV 2004 U.S. B 1 99 PHITLWQRPLVTIRVGGQLKEALLDTGADDTVLEEMDLPGKWKPKMIGGIGGFIKVRQYEEILIEICGHKAIGTVLIGPTPVNIIGRNLLTQLGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84409 LPV 2005 U.S. B 1 99 PQITLWQRPLVTIKIEGQLKEALLDTGADDTVLEEMNLSGRWKPKMIGGIGGFIKVRQYDQKLVEICGHKAVGTVLIGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84411 LPV 2003 U.S. B 1 99 PQITLWQRPVVTVKIGGQLKEALLDTGADDTVLEDINLPGKWKPRMIGGIGGFIKVRQYDQVPVEISGYKAIGTVLIGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84415 LPV 2004 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMSLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84416 LPV 2003 U.S. B 1 99 PQITLWQRPLVKIKVGGQIKEALLDTGADDTVLEEMCLPGRWKPKMIGGIGGFIKVRQYDQILIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84418 LPV 2003 U.S. CRF02_AG 1 99 PQITLWQRPLVTVKLGGQLIEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84424 LPV 2003 U.S. B 1 99 PQITLWQRPLVTIRVGGQLKEALLDTGADDTVLEEMNLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGHKAVGTVLIGPTPVNIIGRNLLTQLGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84427 LPV 2003 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGHKAIGTVLIGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84428 LPV 2003 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGHKAIGTVLIGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84439 LPV 2004 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEQMDLPGRWKPKMIGGIGGFIKVRQYDQVSVEICGQKTVGTVLIGPTPVNIIGRNLLTQLGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84444 LPV 2004 U.S. B 1 99 PQITLWQRPLVSIKIGGQIKEALLDTGADDTVLEEMNLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGHRAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84446 LPV 2003 U.S. C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEQISIEICGKKAIGTVLVGPTPVNIIGRNILTQLGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84447 LPV 2003 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQIPLEICGHKAVGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84450 LPV 2003 U.S. B 1 99 PQITLWQRPVVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWRPKMIGGIGGFIKVRQYDQITIEICGHKATGSVLIGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84456 LPV 2005 U.S. B 1 99 PQITLWQRPLVTIKVGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQILIEICGHKAVGTVLIGPTPVNIIGRNLLTQLGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84471 LPV 2003 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEDMDLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84473 LPV 2003 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGHKAIGTVLIGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84476 LPV 2003 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84477 LPV 2003 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMDLPGKWKPKMIGGIGGFIKVRQYEQILIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84479 LPV 2004 U.S. B 1 99 PQITLWQRPIVTIKIGGQLKEALLDTGADDTVLEEISLPGKWKPKMIGGIGGFIKVRQYDQVPIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84480 LPV 2005 U.S. B 1 99 PQITLWQRPLVTIKIGEQIKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQILIEICGHKAIGTVLIGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84487 LPV 2003 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEIDLPGRWKPKMIGGIGGFIKVRQYDQILIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84488 LPV 2003 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMSLPGRWKPKMIGGIGGFIKVRQYDQVPIEICGHKTIGTVLIGPTPVNIIGRNLLTQLGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84490 LPV 2005 U.S. B 1 99 PHITLWQRPLVTIKIGGQVKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQILIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84491 LPV 2005 U.S. B 1 99 PQITLWQRPLVTIKIGGQLREALLDTGADDTVLEDMSLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGHKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84492 LPV 2003 U.S. B 1 99 PQITLWQRPLVTIRIGGQLKEALLDTGADDTVLEEMNLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84494 LPV 2003 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84497 LPV 2003 U.S. B 8 99 RPLFTLKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQIAIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84499 LPV 2003 U.S. B 1 99 PQITLWQRPLVAIKIGGQQKEALLDTGADDTVLEEMSLPGRWKPKMIGGIGGFIKVRQYDQILVEICGYKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84503 LPV 2003 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGKWKPKMIGGIGGFIKVKQYEQITLEICGHKVIGTVLIGPTPVNIIGRNLLTQLGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84504 LPV 2003 U.S. B 1 99 PQITLWQRPLVTIRIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGHKTVGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84505 LPV 2004 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEVCLPGKWKPKMIGGIGGFIKVRQYDQVPIEICGHKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84506 LPV 2003 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQIQVEICGHKAIGTVLIGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84507 LPV 2003 U.S. B 1 99 PQVTLWQRPLVSVKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGHKATGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84508 LPV 2005 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84511 LPV 2003 U.S. B 1 99 PQITLWQRPLVTIKIGGQIKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQITIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84514 LPV 2004 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQILIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84516 LPV 2005 U.S. B 1 99 PQITLWQRPVVTVKIGGQLKEALLDTGADDTVLEEMNLPGKWKPKMIGGIGGFIKVKQYEQIPIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84518 LPV 2004 U.S. B 1 99 PQITLWQRPLVTIKVGGQIKEALLDTGADDTVLEDMDLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84521 LPV 2004 U.S. CRF01_AE 10 99 LVTIKIEGQLKEALLDSGADDPVLEDINLPGKWKPKMIGGIGGFIKVKQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84524 LPV 2003 U.S. B 1 99 PQITLWQRPIVTVKVGGQLKEALLDTGADDTVLEEIDLPGRWKPKMIGGIGGFIKVRQYDQISLEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84525 LPV 2003 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVVEEMNLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGHKTEGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84526 LPV 2003 U.S. B 1 99 PQITLWQRPIVTIKIGGQLKEALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVRQYEEIPIEICGHRATGTVLVGPTPVNIIGRNLLTQLGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84534 LPV 2004 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVVEEMCLPGKWKPKMIGGIGGFIKVRQYDQIQVDICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84536 LPV 2004 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEDMNLPGRWKPKMIGGIGGFIKVKQYDQIPIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84541 LPV 2004 U.S. B 1 99 PQITLWQRPIVSVKIGGQIKEALLDTGADDTVVEEMNLPGRWKPKMIGGIGGFIKVRQYDQVSVEIYGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84545 LPV 2003 U.S. B 1 99 PQITLWQRPLVIIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQVPIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84547 LPV 2004 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGKWKPKMIGGIGGFIKVRQYDQILVEICGQKAIGSVLIGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84548 LPV 2004 U.S. B 1 99 PQITLWQRPLVVVRIEGQLKEALLDTGADDTVLEDMRLPGNWTPRMIGGIGGFIKVRQYDQIQVEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84552 LPV 2003 U.S. B 1 99 PQITLWQRPLVTIKIGGQIKEPLLDTGADDTVLEEMSLPGRWKPKMIGGIGGFIKVRQYDQIAIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84554 LPV 2004 U.S. B 1 99 PQITLWQRPIVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQVPIEICEHKTIGTVLIGPTPVNIIGRNLLTQLGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84555 LPV 2003 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEELSLPGKWKPKMIGGIGGFIKVRQYDQVLVEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84556 LPV 2003 U.S. B 1 99 PQITLWQRPLVTVKIGGQLKEALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVRQYDQVPIDICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84557 LPV 2003 U.S. B 1 99 PQITLWQRPLVTVKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVKQYEQIPVEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84559 LPV 2004 U.S. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVRQYDQVPIEICGHKVIGTVLVGPTPVNIIGRNLLTQLGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84560 LPV 2003 U.S. B 1 99 PQITLWQRPIVTIRVGDQLKEALLDTGADDTVLEDMSLPGRWKPKMIGGIGGFIKVKQYDQVTIEICGHKTIGTVLVGPTPVNIIGRNLLTQLGCTLNF Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1952 85294 LPV 2007 Zambia C 1 99 PQITLWQRPLVTIKVGGQLKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIAIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85317 LPV 2007 Zambia C 1 99 PQITLWQRPFVTVKVEGQIMEALLETGADDTVLEEINLPGRWKPKIIGGIGGFVKVRQYDQITIEICGKKAIGSVVVGPTPANIIGRNMLTQLGCTLNF Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85318 LPV 2007 Zambia C 1 99 PQITLWQRPLVSVKVGGQIREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQITIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85340 LPV 2008 South Africa C 1 99 PQITLWQRPLVTIKIEGQIKEALLDTGADDTVLEEINLTGKWKPKMIGGIGGFIKVRQYEQIAIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85386 LPV 2008 South Africa C 13 99 IKVGAQIKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVKQYDQIPIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85388 LPV 2008 South Africa C 1 99 PQITLWQRPLVQIKVGGQTKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1970 90266 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90272 LPV 2008 South Africa C 1 99 PQITLWQRPIVSIKVGGQTREALLDTGADDTVLEDINLPGKWKPKIIGGIGGFVKVREYDQVPIEICGKKAIGTVVVGPTPANIIGRNMLTQLGCTLNF Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90283 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQVKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90286 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEETSLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90288 LPV 2008 South Africa C 1 99 PQITLWQRPIVAIKVEGQLKEALLDTGADDTVLEDINLPGKWKPRMIGGIGGFIKVRQYDQITIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90290 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQTKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90292 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIRVGGQTKEALLDTGADDTVLEEISLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90294 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYEEIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90296 LPV 2009 South Africa C 1 99 PQITLWQRPLVTIKVGGQVKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1976 92376 LPV 2008 Cambodia CRF01_AE 1 99 PQITLWQRPVVTVKIEGQLREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQICIEICGKKAIGAVLVGPTPANIIGRNMLTQIGCTLNF Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1978 90335 LPV 2006 U.K. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKLIGGIGGLIKVRQYDQVHIEICGHKVIGTVLIGPTPVNIIGRNLLTQLGCTLNF Barber, TJ 2012 22258921 J Antimicrob Chemother Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. 1978 90336 LPV 2005 U.K. A 1 99 PQITLWQRPIVTVKIEGQLKEALLDTGADDTVLEEINLPGKWKPKIIGGIGGFIKVRQYDQITIEICGKKAIGTVVVGPTPVNVIGRNMLTQIGCTLNF Barber, TJ 2012 22258921 J Antimicrob Chemother Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. 1978 90337 LPV 2005 U.K. C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFVKVKQYDQILIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Barber, TJ 2012 22258921 J Antimicrob Chemother Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. 1978 90338 LPV 2006 U.K. B 1 99 PQITLWQRPVVTVRIGGQLKEALLDTGADDTVLEEMNLPGRWKPKIIGGIGGFVKVRQYDQIPVEICGHKAIGTVVVGPTPCNIIGRNLLTQIGCTLNF Barber, TJ 2012 22258921 J Antimicrob Chemother Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. 1978 90339 LPV 2003 U.K. J 1 99 PQITLWQRPIVNIRVEGQLREALLDTGADDTVLEEIDLPGKWKPKMIGGIGGFVKVRQYNDILIEVEGKKVRGTVLVGPTPANIIGRNMLTQLGCTLNF Barber, TJ 2012 22258921 J Antimicrob Chemother Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. 1978 90340 LPV 2003 U.K. C 4 99 TLWQRPLVSIKIGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVREYEQIAIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Barber, TJ 2012 22258921 J Antimicrob Chemother Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. 1978 90341 LPV 2002 U.K. B 1 99 PHITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMSLPGRWKPKIIGGIGGFIKVRQYDQIMVEICGHTAIGTVLIGPTPVNIIGRNLLTQIGCTLNF Barber, TJ 2012 22258921 J Antimicrob Chemother Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. 1978 90342 LPV 2006 U.K. CRF02_AG 1 99 PQITLWQRPIVTVKIEGKPIEALLDTGADDTVLEDITLSGKWKPKIIGGIGGFIKVRQYDQVLIEICGKRAIGAVLVGPTPVNVIGRNMLTQIGCTLNF Barber, TJ 2012 22258921 J Antimicrob Chemother Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. 1978 90343 LPV 2002 U.K. B 1 99 PQITLWQRPVVTIRVGGQLKEALLDTGADDTVLEDINLPGKWKPKIIGGIGGFVKVRQYDQIPIEICGHKVIGTVLVGPTPSNIIGRNLLSQIGCTLNF Barber, TJ 2012 22258921 J Antimicrob Chemother Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. 1978 90344 LPV 2007 U.K. G 1 99 PQITLWQRPLVTVRIGGQLIEALLDTGADDTVLEQIKLPGKWKPKMIGGIGGFVKVRQYDQVPIEIEGKKVIGTVLVGPTPINIIGRNMMTQMGCTLNF Barber, TJ 2012 22258921 J Antimicrob Chemother Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. 1978 90345 LPV 2005 U.K. C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVVVGPTPVNIIGRNMLTQLGCTLNF Barber, TJ 2012 22258921 J Antimicrob Chemother Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. 1978 90346 LPV 2004 U.K. D 1 99 PQITLWQRPLVTIRVGGQIKEALLDTGADDTVLEEMNLPGKWKPKMIGGIGGFIKVKQYDQILVDICGHKAIGTVLVGPTPVNIVGRNLLTQIGCTLNF Barber, TJ 2012 22258921 J Antimicrob Chemother Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. 1978 90347 LPV 2007 U.K. CRF01_AE 1 99 PQITLWQRPFVTVKVGGQLKEALLDTGADDTVLEDINLPGKWKPKIIGGIGGFIKVRQYDQICIEICGKKAIGPVLVGPTPVSIIGRNMLTQIGCTLNF Barber, TJ 2012 22258921 J Antimicrob Chemother Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. 1978 90348 LPV 2008 U.K. B 1 99 PQITLWQRPLVAVRIGGQLKEALLDTGADDTVVEEMTLPGKWKPKMIGGIGGFIKVREYDQVPVEICGHKAIGTVLVGPTPVNIIGRNLLTEIGCTLNF Barber, TJ 2012 22258921 J Antimicrob Chemother Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. 1978 90349 LPV 2007 U.K. C 1 99 PQITLWQRPFVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFVKVRQYDQITIEICGKKAIGTVLVGPTPANIIGRNMLTQLGCTLNF Barber, TJ 2012 22258921 J Antimicrob Chemother Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. 1978 90350 LPV 2005 U.K. CRF02_AG 1 99 PQITLWQRPLVTVKLGGQIIEALLDTGADDTVLEEISLPGKWKPKMIGGIGGFVKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Barber, TJ 2012 22258921 J Antimicrob Chemother Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. 1978 90351 LPV 2006 U.K. A 1 99 PQITLWQRPFVTVKIGGQLREALLDTGADDTIIEDINLPGKWKPKIAGGIGGFIKVKQYDQVLIEICGKRAIGSVLVGPTPVNIIGRNVLTQIGCTLNF Barber, TJ 2012 22258921 J Antimicrob Chemother Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. 1978 90352 LPV 2007 U.K. CRF02_AG 1 99 PQITLWQRPLVTVRIGGQLIEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFVKVRQYDQILLEICGKRAIGTVLVGPTPANIIGRNMLTQIGCTLNF Barber, TJ 2012 22258921 J Antimicrob Chemother Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. 1978 90353 LPV 2006 U.K. B 1 99 PQITLWRRPLVTIKVGGQLKEALLDTGADDTVLEDMSLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGHKAIGTVLVGPTPVNVIGRNLLTQIGCTLNF Barber, TJ 2012 22258921 J Antimicrob Chemother Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. 1978 90354 LPV 2007 U.K. C 1 99 PQITLWQRPIVSIKVGGQVKEALLDTGADDTVLEEINLPGKWKPRIIGGIGGFVKVRQYDQIPIEICGKKAIGSVLVGPTPANIIGRNLLTQLGCTLNF Barber, TJ 2012 22258921 J Antimicrob Chemother Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. 1978 90355 LPV 2005 U.K. B 1 99 PQITLWQRPLVTIKIGGQLREALLDTGADDTVLEDIDLPGRWKPKMIGGIGGLIKVRQYDQVPIDICGHKTIGTVLIGPTPVNIIGRNLLTQLGCTLNF Barber, TJ 2012 22258921 J Antimicrob Chemother Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. 1978 90356 LPV 2006 U.K. C 1 99 PQITLWQRPFVTIKVGDQIKEALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVRQYEQIPIEICGKKAIGTVLVGPTPANIIGRNMLTQLGCTLNF Barber, TJ 2012 22258921 J Antimicrob Chemother Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. 1978 90357 LPV 2005 U.K. B 1 99 PQITLWQRPLVTVKIGGQLKEALLDTGADDTVLEEMNLPGKWKPKMIGGIGGFIKVKEYDNILIEICGYKAIGTVLIGPTPVNIIGRNLLTQIGCTLNF Barber, TJ 2012 22258921 J Antimicrob Chemother Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. 1978 90358 LPV 2004 U.K. D 4 99 TLLQRPLVTIKIEGQIKEALLDTGADDTVLEEMNLPGKWKPKMIGGIGGFIKVRQYDQVHIEICGQKAIGTVLVGPTPVNIVGRNLLTQIGCTLNF Barber, TJ 2012 22258921 J Antimicrob Chemother Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. 1978 90359 LPV 2006 U.K. B 1 99 PQITLWQRPIVTIKIGGQLKEALLDTGADDTILEEINLPGKWKPKIVGGIGGFVKVRQYDQVLVEICGYKTIGTVLVGPTPANIIGRNLLTQLGCTLNF Barber, TJ 2012 22258921 J Antimicrob Chemother Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. 1978 90360 LPV 2006 U.K. B 1 99 PQITLWQRPLVTIKVGGQLKEALLDTGADDTVLEEMNLPGKWKPKMVGGIGGFIKVRQYDQISIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Barber, TJ 2012 22258921 J Antimicrob Chemother Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. 1978 90361 LPV 2007 U.K. B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEDIDLPGRWKPKMIGGIGGFVKVRQYDRIPIEICGHKAIGTVLVGPTPINIIGRNLLTQLGCTLNF Barber, TJ 2012 22258921 J Antimicrob Chemother Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. 1978 90362 LPV 2002 U.K. B 1 99 PQITLWQRPLVTIKIGGMLKEALLDTGADDTVLEEMNLPGRWKPKIIGGIGGFIKVRQYDQIPIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Barber, TJ 2012 22258921 J Antimicrob Chemother Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. 1978 90363 LPV 2007 U.K. A 1 99 PQITLWQRPLVTVKIGDQLREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFVKVKQYEQVIIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Barber, TJ 2012 22258921 J Antimicrob Chemother Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. 1978 90364 LPV 2004 U.K. B 1 99 PQITLWQRPIVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWRPKMIGGIGGFIKVKQYDQIPIEISGHKAIGTVLVGPTPVNIIGRNLMTQLGCTLNF Barber, TJ 2012 22258921 J Antimicrob Chemother Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. 1978 90365 LPV 2005 U.K. B 1 99 PQITLWQRPLVTIKVGGQLKEALLDTGADDTVFEEMNLPGKWKPKMIGGIGGFIKVRQYDQVPVEISGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Barber, TJ 2012 22258921 J Antimicrob Chemother Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. 2011 94934 LPV 2009 Uganda D 1 99 PQITLWQRPLVTVKIGGQLKEALLDTGADDTVIEETNLSGKWKPKMIGGIGGFIKVRQYDQISVEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94943 LPV 2007 Uganda D 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEDMNLPGKWKPKMIGGIGGFIKVKQYDQIPVEICGYKAVGTVLVGPTPVNIIGRNLLTQIGCTLNF Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94947 LPV 2008 Uganda B 1 99 PQITLWQRPLVAVKIGGQLKEALLDTGADDTVVEEMNLPGKWKPKMIGGIGGFIKVRQYDQILVEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94951 LPV 2009 Uganda D 1 99 PQITLWQRPVVTVKIGGQLKEALLDTGADDTVLEEMNLPGKWKPKMIGGIGGFIKVKQYDQILVEICGHKAIGSVLIGPTPVNIIGRNLLTQIGCTLNF Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94956 LPV 2008 Uganda D 1 99 PQITLWQRPLVTVKIGGQLKEALLDTGADDTVLEEINLPGKWKPRMIGGIGGFIKVRQYDQILVEICGHKAVGTVLVGPTPVNIIGRNLLTQIGCTLNF Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94957 LPV 2007 Uganda D 1 99 PQITLWQRPIVTVKIGGQLREALLDTGADDTVVEEINLPGKWKPKMIGGIGGFIKVRQYDQILVEICGYKATGTILVGPTPVNIIGRNLLTQIGCTLNF Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94959 LPV 2009 Uganda A 1 99 PQITLWQRPLVTVKIGGQLIEVLLDTGADDTVLENINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLIGPTPVNIIGRNMLTQIGCTLNF Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2122 115222 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPRMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115225 LPV 2010 South Africa C 1 99 PQITLWQRPIVTIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115229 LPV 2009 South Africa C 1 99 PQITLWQRPLVPIKVEGQTKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQVYLEICGKKAIGTVLVGATPINIIGRNILTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115232 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115237 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQTKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115238 LPV 2006 South Africa C 46 99 MIGGIGGSIKVRQYDQISIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115239 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115244 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVGGQVKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKRAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115245 LPV 2012 South Africa C 1 99 PQITLWQRPLVTIKIGGQTREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115248 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKIGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEEIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115250 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKRAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115256 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIIVGGQTREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYEQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115260 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKIGGQIREALLDTGADDTVLEEIDLPGRWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115265 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEDMNLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115266 LPV 2012 South Africa C 1 99 PQITLWQRPLVTISVGGQTREALLDTGADDTVLEEINLPGKWKPKIIGGIGGFVKVRQYDHILIEICGKKAIGTVLVGPTPANIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115268 LPV 2011 South Africa C 1 99 PQITLRQRPLVTIKIGDQLREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDEILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115270 LPV 2011 South Africa C 1 99 PQITLWQRPLVTIKIEGQIKEALLDTGADDTVIEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115276 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQEREALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVKQYDQIPVEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115277 LPV 2012 South Africa C 1 99 PQITLWQRPLVTIKVGGQTKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115278 LPV 2009 South Africa C 1 99 PQITLWQRPLVTIKVGGQIKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115281 LPV 2010 South Africa C 1 99 PQITLWQRPVVTIKVGGQVREALLDTGADDTVLEDINLPGKWKPKIIGGIGGLVKVRQYEEILIEICGKKAIGTVLVGPTPANIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115282 LPV 2007 South Africa C 1 99 PQITLWQRPFVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPANIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115286 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVEGQIMEALLDTGADDTVLEDINLPGRWKPKIIGGIGGFVKVRQYDQITIEICGKKAIGSVLVGPTPANIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115287 LPV 2010 South Africa C 26 99 TGADDTVLEDINLPGKWKPKIIGGIGGFLKVRQYDQIPIEICGKKAIGTVVVGPTPVNVIGRNMLTQIGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115294 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGEIREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115295 LPV 2009 South Africa C 1 99 PQITLWQRPLVTIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115298 LPV 2011 South Africa C 1 99 PQITLWQRPIVSIKVGGQTREALLDTGADDTVLENINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGQKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115307 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVEGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115316 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEISLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115317 LPV 2007 South Africa C 1 99 PQITLWQRPLVSIKVGGQVKEALLDTGADDTVLEELSLPGKWKPKMIGGIGGFIKVRQYEQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115318 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKIGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQITIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115319 LPV 2009 South Africa C 1 99 PQITLWQRPFVSIKVGGQTTEALLDTGADDTVFEELNLPGKWKPKMIGGIGGFVKVRQYDQIPIEICGKKAIGTVLVGPTPANIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115320 LPV 2011 South Africa C 1 99 PQITLWQRPLVTIKVGGQLKEALLDTGADDTVLEDINLPGKWKPRMIGGIGGFIKVKQYDEIPMEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115321 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEDINLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115325 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVEGQIKEALLDTGADDTVLEEINLSGRWKPKMIGGIGGFIKVRQYEQILIEICGKKAIGTVLVGPTPVNIIGRNILTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115328 LPV 2011 South Africa C 1 99 PQITLWQRPFVTIKVEGQIREALLDTGADDTVLEDINLPGKWKPKLIGGIGGFVKVRQYDNIHIEICGKKAIGTVVVGPTPANIIGRNILTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115333 LPV 2010 South Africa C 1 99 PQITLWQRPLVTIKIGDQIKEALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVRQYDQITIEICGKKAIGTVLVGPTPVNIIGRNMMTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115340 LPV 2009 South Africa A 23 99 LLDTGADDTVLEDINLPGKWKPRMIGGIGGFIKVKQYDQITIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115348 LPV 2011 South Africa C 1 99 PQITLWQRPLVTIKVGGQIKEALLDTGADDTVLEDITLPGKWKPKMIGGIGGFIKVKQYDEIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115350 LPV 2012 South Africa C 1 99 PQITLWQPPLVTIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115351 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQVKEALLDTGADDTVLEEINLPGKWKPRMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115352 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEMSLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115360 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115370 LPV 2008 South Africa C 14 99 KIGGQIKEALLDTGADDTVLQEINLPGKWKPKMIGGIGGFVKVRQYDQIPIEICGKKAIGTVLVGPTPANIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115375 LPV 2007 South Africa C 1 99 PQITLWQRPLVSIKVGGQTKEALLDTGADDTVLEEISLPGKWKPKMIGGIGGFIKVRQYDQIAIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115377 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIRVEGQVKEALLDTGADDTVLEEIKLPGKWRPKMIGGIGGFIKVKQYDQITIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115378 LPV 2010 South Africa C 1 99 PQITLWQRPLVTIKVGGQTKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115382 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIQLEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115383 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEELNLPGKWKPKMIGGIGGFIKVRQYEQIPIEIGGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115384 LPV 2011 South Africa C 1 99 PQITLWQRPLVTIKVGGQIKEALLDTGADDTVLEDLELPGKWKPKMIGGIGGFIKVRQYDQILVEICGKKTIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115393 LPV 2010 South Africa CRF02_AG 1 99 PQITLWQRPLVKVKIGEQLIEALLDTGADDTVLEEISLPGKWKPKMIGGIGGFIKVRQYDQILIEICGHKAMGTVLVGPTPVNIIGRNMLTQIGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115396 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115397 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKIEGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115398 LPV 2010 South Africa C 1 99 PQITLWQRPLVTIKVGGQLKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKALGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115401 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKIGGQTREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQITIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115406 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNILTQIGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115407 LPV 2011 South Africa C 1 99 PQITLWQRPLVTIKVGGQIKEALLDTGADDTVLEEIDLPGKWKPKMIGGIGGFIKVRQYDQIQIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115410 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQTREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115411 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQTKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEEILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115418 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQTREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115421 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVEGQIKEALLDTGADDTVLEDINLPGKWKPRMIGGIGGFIKVKQYEEISIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115422 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKIEGQIKEALLDTGADDTVLEDMNLPGR*KPKMIGGIGGFIKVRQYDQIAIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115427 LPV 2006 South Africa C 1 99 PQITLWQRPLVSIKVGGQTREALLDTGADDTVLEDIDLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115430 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKIGGQIREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115431 LPV 2010 South Africa C 1 99 PQITLWQRPLVTIKVGGQTKEALLDTGADDTVLEDINLPGRWKPKMIGGIGGFIKVRQYDQISIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115437 LPV 2011 South Africa C 1 99 PQITLWQRPLVTIKVGGQTKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115439 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKIGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115440 LPV 2010 South Africa C 1 99 PQITLWQRPLVTIKVEGQIREALLDTGADDTVLEEITLLGKWKPKMIGGIGGFIKVRQYEQVLIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115441 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQTREALLDTGADDTVLEEINLPGKWRPKMIGGIGGFIKVKQYDNITIDICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115442 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLEDIDLPGKWKPKMIGGIGGFIRVKQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115445 LPV 2010 South Africa C 1 99 PQISLWQRPFVSIKVGGQITEAILDTGADDTVLEDIDLPGKWKPVMIGGIGGFVKVKQYDQIPIEICGKEVMSTVLVGSTPVNVIGRNVLTKLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115446 LPV 2009 South Africa C 1 99 PQITLWQRPLVTIKVGGQVKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKRAIGTVLVGPTPINIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115447 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQVKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVKQYEQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115449 LPV 2007 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLEQIDLPGKWKPKMIGGIGGFIKVRQYDQIVIEICGKKAVGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115452 LPV 2008 South Africa C 1 99 PQITFWQRPLVSIKIGGQIKEALLDTGADDTVLEEINLPGKWKPRMIGGIGGFIKVRQYEQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115453 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115460 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLEELDLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115462 LPV 2011 South Africa C 1 99 PQITLWQRPLVAIKVGGQIREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVKQYEEIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115478 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115481 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIRVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQITIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115488 LPV 2007 South Africa C 1 99 PQITLWQRPLVTIRVGGQIKEALLDTGADDTVLEEIDLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115492 LPV 2012 South Africa C 1 99 PQITLWQRPFVTVKIEGQTMEALIDTGADDTVFEDINLPGKWKPKIIGGIGGFVKVRQYDNIHIEICGKKAVGPVLVGPTPANIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115493 LPV 2011 South Africa C 1 99 PQITLWQRPFVSIKVGGQTREALLDTGADDTVLEEINLPGKWRPKIIGGIGGFVKVRQYDQIVIEICGKKAIGTVLVGPTPANIIGRNILTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115497 LPV 2009 South Africa C 1 99 PQITLWQRPLVTIKVGGQIKEALLDTGADDTVLEEMSLPGKWKPKMIGGIGGFIKVRQYDQILIEICGQKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115499 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVEGQIREALLDTGADDTVLEDINLPGKWKPRMIGGIGGFIKVRQYEEVTIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115517 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYEEILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115519 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVGGQTKEALLGTGADDTVLEEIDLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115520 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQVKEALLDTGADDTVLEETNLPGKWKPKMIEGIGGFIKVRQYEEILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115528 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVEGQIREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIAIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115530 LPV 2006 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115531 LPV 2011 South Africa C 1 99 PQITLWQRPLVTIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIQIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115534 LPV 2012 South Africa C 1 99 PQITLWQRPFVSIKVGGQTREALLDTGADDTVLEEINLPGKWKPKIIGGIGGFVKVRQYDQIVIEICGKKAIGTVVVGPTPANIIGRNILTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115537 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQTREALLDTGADDTVLEDIDLPGKWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115538 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQVKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYEEIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115539 LPV 2012 South Africa B 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGHKAVGTVLIGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115542 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKIGGQIREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115544 LPV 2009 South Africa C 1 99 PQITLWQRPLVEIKVGGQIKEALLDTGADDTVLEELSLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115546 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKIGGQTREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115547 LPV 2012 South Africa C 1 99 PQITLWQRPLVTIKVGGQIKEALLDTGADDTVLEELDLPGKWKPKMIGGIGGFIKVRQYEQVPIEICGKKAVGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115556 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQTKEALLDTGADDTVLEDMNLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115557 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQITIEICGKKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115559 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQVLIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115560 LPV 2008 South Africa C 1 99 PQITLWQRPFVSVKIGGQTMEALIDTGADDTVFEDINLPGKWKPKIIGGIGGFVKVRQYDNIPIEICGKKAIGSVVVGPTPANIIGRNMLTQLGCTINF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115561 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQVKEALLDTGADDTVLEETNLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115564 LPV 2010 South Africa C 1 99 PQITLWQRPLVSVKVEGQITEALLDTGADDTVLEEINLPGKWKPVMIGGIGGFVKVRQYEEILIEVCGKRAVGTVLVGPTPINVIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115566 LPV 2008 South Africa C 1 99 PQITLWQRPLVTIKVGGQIKEALLDTGADDTVLEDIDLPGRWKPKMIGGIGGFIKVKQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115567 LPV 2010 South Africa C 1 99 PQITLWQRPLVTIIVGGQTREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDHILIEICGKKATGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115568 LPV 2011 South Africa C 1 99 PQITLWQRPLVSVKIGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115570 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIRVGGQIKEALLDTGADDTVLEEIDLPGRWKPKMIGGIGGFIKVRQYEQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115571 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVEGQIKEALLDTGADDTVLEEMSLPGRWKPKMIGGIGGFIKVRQYDQIHIEICGKKAIGTVLIGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115572 LPV 2007 South Africa C 1 99 PQVTLWQRPLVSIKVGGQIKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYEQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115574 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQTREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVKQYDQIPIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115577 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKIGGQIKEALLDTGADDTVLEDLNLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115579 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVGGQTKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115582 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFVKVRQYDQILIEICGKKAIGTVLVGPTPINIIGRNILTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115583 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIRIEGQIKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115584 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQTKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDHIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115585 LPV 2009 South Africa C 1 99 PQITLWQRPMVTIKVGGQMKEALLDTGADDTVLEDMNLPGKWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115586 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115590 LPV 2011 South Africa C 1 99 PQITLWQRPLVTIKVEGQTKEALLDTGADDTVLEELSLPGRWKPKMIGGIGGFIKVRQYDQITIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115593 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQVKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQITIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115599 LPV 2011 South Africa G 1 99 PQITLWQRPIVTVKIGGQLIEALLDTGADDTVLEQIDLPGKWKPKMIGGIGGFVKVKQYDQIPIEIEGKKTIGTVLVGPTPMNIIGRNILTQIGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115601 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115602 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEISLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115605 LPV 2007 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115606 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIRVGGQVKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115607 LPV 2007 South Africa C 1 99 PQITLWQRPLVTINVGGQTREALLDTGADDTVLEEIKLPGNWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115608 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKMKQYDHIPIEICGKQAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115612 LPV 2007 South Africa C 1 99 PQITLWQRPLVTIKVEGQIKEALLDTGADDTVLENINLTGKWKPRMIGGIGGFIKVRQYDQITIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115613 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGETREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115614 LPV 2010 South Africa C 1 99 PQITLWQRPVVSIKVGGQIREALLDTGADDTVLQEISLPGKWKPKMIGGIGGFVKVREYDQIPIEICGKRVIGTVVVGPTPANIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115615 LPV 2010 South Africa C 1 99 PQITLWQRPMVSIKVGGQTKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115618 LPV 2010 South Africa C 1 99 PQITLWQRPMVTIKVGGQLKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115630 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLENIDLPGKWKPKMIGGIGGFIKVKQYEQIVIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115633 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPRMIGGIGGFIKVRQYDQITIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115634 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDNILIEICGKKAMGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115635 LPV 2010 South Africa C 1 99 PQITLWQRPLVTINVGGQIKEALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115638 LPV 2009 South Africa C 1 99 PQITLWQRPFVSIKVGGQIKEALLDTGADDTVLEEINLPRKWKPKMIGGIGGFIKVRQYEEIPIEICGKKAIGTVLVGPTPANIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115642 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLIGPTPINIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115643 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115645 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVGDQIKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115646 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGEIREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115649 LPV 2007 South Africa C 1 99 PQITLWQRPLVTIKVGGQIKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDEILIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115650 LPV 2010 South Africa C 1 99 PQITLWQRPLVTIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115652 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQTREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115660 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVEGQVKEALLDTGADDTVLEELNLPGRWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115663 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQVKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEEILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115669 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDEIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115672 LPV 2011 South Africa C 1 99 PQITFWQRPLVSIKIGSQIREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDEIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115675 LPV 2009 South Africa C 1 99 PQITLWQRPLVTINVGGQIKEALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115677 LPV 2011 South Africa C 1 99 PQITLWQRPLVTIKVGGQVKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115681 LPV 2010 South Africa C 1 99 PQITLWQRPFVTIKVAGQTKEALLDTGADDTVLEDIDLPGRWKPKMIGGIGGFIKVKQYEEIPIEICGKKAIGTVVVGPTPANIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115683 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQVREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115685 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115688 LPV 2011 South Africa C 1 99 PQITLWQRPLVTIKVGGQIKEALLDTGADDTVLEDLNLPGKWKPKMIGGIGGFIKVRQYEQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115690 LPV 2010 South Africa C 1 99 PQITLWQRPLVTIKVGGQTKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115691 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQITEALLDTGADDTVLEDINLPGKWKPRMAGGIGGLIKVRQYEQIPIEICGKKVIGTVLVGPTPVNIIGRSLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115702 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKIGGQTREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115703 LPV 2008 South Africa C 1 99 PQITLWQRPIVTIKVGGQIKEALLDTGADDTVLEEINLQGKWKPKMIGGIGGFIKVRQYDQITIEICGQKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115705 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKIGGQIKEALLDTGADDTVLEEVNLPGKWKPKMIGGIGGFIKVRQYEQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115714 LPV 2010 South Africa C 1 99 PQITLWQRPCVTIKVGGQVKEALLYTGADDTVLEEINLPGKWKPKIIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPANIIGRNMLTQIGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115720 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEDINLPGKWKPRMIGGIGGFIKVRQYEEISIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115721 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEMNLPGKWKPKMIGGIGGFIKVRQYDQIQIEICGKKAIGSVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115723 LPV 2012 South Africa C 1 99 PQITLWQRPLVTIKVGGQIKEALLDTGADDTVLEEMSLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLIGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115726 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKIGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEEIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115733 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVEGQIKEALLDTGADDTVLEEMSLPGRWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115734 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVEGQIREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKRAIGSVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115735 LPV 2011 South Africa C 1 99 PQITLWQRPLVTIKVGGQTKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQISIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115739 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQITIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115740 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQVREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDEIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115741 LPV 2009 South Africa C 1 99 PQITLWQRPLVTIKVGGQIKEALLDTGADDTVLEEMSLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKALGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115742 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIRVEGQIREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQVSIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115749 LPV 2012 South Africa C 1 99 PQITLWQRPLVTIKVGGQVKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115750 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEMNLPGKWKPKMIGGIGGFIKVRQYDQIQIEICGKKAIGSVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115754 LPV 2011 South Africa C 1 99 PQITLWQRPLVTIKIGGQTKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115755 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115759 LPV 2009 South Africa C 1 99 PQITLWQRPLVTIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIVIDICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115760 LPV 2012 South Africa C 1 99 PQITLWQRPLVTIKVGGQIKEALLDTGADDTVLEELSLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115761 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115762 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEEIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115764 LPV 2010 South Africa C 1 99 PQITLWQRPIVSIKVEGQIREAILDTGADDTVLEDINLPGKWKPKIIGGVGGFVKVRQYDNIHIEICGKKVMGTVLVGPTPANIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115765 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKIGGQTKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115770 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQTREALLDTGADDTVLEDMNLPGRWKPKMIGGIGGFIKVRQYDEIPIEICGKKAIGTVLIGPTPINIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115774 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQTREALLDTGADDTVLEDINLPGRWKPKMIGGIGGFIKVRQYDQISIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115777 LPV 2010 South Africa C 1 99 PQITLWQRPIVSIKIGGQIREALLDTGADDTVLEEINLPGKWKPKIIGGIGGFVRVRQYEQVPIEICGKKVIGTVVVGPTPANIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115780 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQVREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAVGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115781 LPV 2011 South Africa C 1 99 PQITLWQRPLVTIKVGGQVKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKRAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115782 LPV 2007 South Africa C 1 99 PQITLWQRPLVSIKVGGQTKEALLDTGADDTVLEEMSLPGKWRPKMIGGIGGFIKVRQYDEIPIEISGKKAIGTVLIGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115783 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIRVGGQVREALLDTGADDTVLEDIDLPGRWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115785 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKIGGQIREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115788 LPV 2010 South Africa A 1 99 PQITLWQRPLVSVKVEGQLREALLDTGADDTVLEDINLPGRWKPKMIGGIGGFIKVRQYDQISLEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115789 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115791 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKIGGQIKEALLDTGADDTVLEEMSLSGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLIGPTPINIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115795 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKIGGQIREALLDTGADDTVLEEIDLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115797 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115801 LPV 2010 South Africa C 1 99 PQITLWQRPLVTIKVGGQIKEALLDTGADDTVLEDINLPGRWKPKMIGGIGGFIKVKQYDQILIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115807 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLEEIDLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115809 LPV 2008 South Africa C 1 99 PQITLWQRPIVTISVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQITMEICGKKAVGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115810 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEDINLPGKWKPKIIGGIGGFIKVRQYDEIPIEICGKKTIGTVVVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115813 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQVKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGSVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115814 LPV 2009 South Africa C 1 99 PQITLWQRPLVSVKVAGQTREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDHIVIEICGKKATGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115816 LPV 2010 South Africa C 1 99 PQITLWQRPLVTIKVGGHVREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVKQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115819 LPV 2011 South Africa C 1 99 PQITLWQRPIITVKIEGKTREALLDTGADDTVLEEINLPGKWIPKMIGGIGGFIKVKQYDQITIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115825 LPV 2007 South Africa C 1 99 PQITLWQRPIVSIKVGGQTREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEEVTIDICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115826 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNILTQIGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115828 LPV 2010 South Africa C 1 99 PQITLWQRPFVTIKVGGQIREALIDTGADDTVFEDIELPGKWKPKLIGGIGGFVKVRQYEQVLIEICGKKAIGTVLVGPTPANIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115829 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVREYKEIPIEICGKKAIGTVLVGPTPVNVIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115830 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGDQTREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQITIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115831 LPV 2010 South Africa C 1 99 PQITLWQRPLVTIKVGGQLKEALLDTGADDTVLEEISLPGKWKPKMIGGIGGFIKVRQYDQISIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115837 LPV 2009 South Africa C 1 99 PQITLWQRPLVSVKIGGQIREALLDTGADDTVLEEISLPGKWKPKMIGGIGGFVKVRQYEEIPIEICGKKAIGTVLVGPTPMNIIGRNMLTQIGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115841 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQTKEALLDTGADDTVLEEISLPGKWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115842 LPV 2010 South Africa C 1 99 PQITLWQRPLVTIRVGGQIKEALLDTGADDTVLEELSLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115843 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQTKEALLDTGADDTVLEEISLPGKWKPKMIGGIGGFIKVRQYDEIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115844 LPV 2010 South Africa C 1 99 PQITLWQRPLVTIKVGGQIKEALLDTGADDTVLEEITLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115845 LPV 2011 South Africa H 1 99 PQITLWQRPLVSIKVGGQIREALIDTGADDTILEDINLPGKWKPRMAGGIGGFIKVRQYEQVPIEICGKKAIGTVLIGPTPINIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115846 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKIGGQTREALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVRQYDQIAIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115847 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115849 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEDINLPGKWKPRMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115852 LPV 2011 South Africa C 1 99 PQITLWQRPLVTIKVGGQTKEALLDTGADDTVLEEMNLSGKWKPKMIGGIGGFIKVRQYDEIPIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115853 LPV 2006 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115854 LPV 2009 South Africa C 1 99 PQITLWQRPFVTIKVEGQLREALLDTGADDTVLEEINLSGKWKPKMIGGIGGFIKVRQYEQICIEICGKKAIGTVLVGPTPANIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115858 LPV 2007 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQVPIEICGKKAIGSVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115859 LPV 2010 South Africa A 1 99 PQITLWQRPLVTVKIGGQLREALLDTGADDTVFEEINLPGKWKPKMIGGIGGFIKVRQYEEILIEICGKKAIGTVLVGPTPVNIIGRNMLTQVGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115864 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQTREALLDTGADDTVLEDIDLPGRWKPKMIGGIGGFIKVKQYEEIPIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115865 LPV 2006 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVRQYDQIQIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115867 LPV 2011 South Africa J 1 99 PQITLWQRPLVPIKVGGQIREALLDTGADDTVLEDIDLPGRWKPKMIGGIGGFIKVKQYDQITIEICEKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115868 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIRVGGQTKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIQIEICGKKAVGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115869 LPV 2011 South Africa C 1 99 PQITLWQRPLVTIKIGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115879 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEMKLPGIWKPKMIGGIGGFIKVRQYEQIPIEICGKKAIGAVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115884 LPV 2011 South Africa B 1 99 PQITLWQRPLVTVKVGGQLMEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILVEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115886 LPV 2011 South Africa C 1 99 PQITLWQRPIVSIRVGGQDKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGAVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115887 LPV 2010 South Africa C 1 99 PQITLWQRPLVTIKVGGQIREAFLDTGADDTVLEDINLPGKWKPKIIGGIGGFVKVREYDQIPIEICGKKAIGTVVVGPTPANIIGRNMLTQIGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115891 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIQIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115898 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVEGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQITIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115900 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEETSLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115901 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEDVNLPGKWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115903 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQTREALLDTGADDTVLEDINLPGKWKPRMIGGIGGFIKVRQYDQISIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115905 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDNILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115907 LPV 2011 South Africa C 1 99 PQITLWQRPLVTIKVGGQIKEALLDTGADDTVLEEMSLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115908 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVGGQTREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115916 LPV 2011 South Africa C 1 99 PQITLWQRPRVSIKVGGQIREALLDTGADDTVLEDINLPGKWKPKIIGGVGGFVKVRQYDQIPIEICGRQVIGTVLVGPTPANIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115918 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVEGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115920 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEEILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115925 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQVKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115928 LPV 2007 South Africa C 1 99 PQITLWQRPLVTIKIGDQIKEALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115930 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLEDIDLPGKWKPKMIGGIGGFIKVKQYDQVLIEICGKKTIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115932 LPV 2006 South Africa C 24 99 LDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQIVIEICGKXAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115934 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVKQYEEILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115939 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQTKEALLDTGADDTVLKEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVVVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115941 LPV 2011 South Africa C 1 99 PQITLWQRPIVSIKVGGQVKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDHIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115945 LPV 2012 South Africa C 1 99 PQITLWQRPLVTIKVGGLIKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115947 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKIGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115952 LPV 2011 South Africa C 1 99 PQITLWQRPFVPIKVEGQPMEALLDTGADDTVLEEINLPGRWKPKIIGGIGGFVKVRQYDQITVEICGKKAIGTVVVGPTPANIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115957 LPV 2011 South Africa C 1 99 PQITLWQRPLVTINVEGQTREALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVRQYDQITIEICGKKAIGTVLVGPTPVNIIGRNILTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115962 LPV 2011 South Africa C 1 99 PQITLWQRPIVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQITIEICGQKATGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115963 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115964 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQVREALLDTGADDTVLEDIDLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115971 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVGGQVKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115975 LPV 2009 South Africa C 23 99 LLDTGADDTVLEEINLPGKWKPRMIGGIGGFIKVRQYDQISIEICGKKAIGTVLVGPTPVNIIGRNILTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115980 LPV 2012 South Africa C 1 99 PQITLWQRPVVSIRVEGQIKEALLDTGADDTVLEEINLPGRWKPRMIGGIGGFIKVRQYDQITIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115981 LPV 2011 South Africa C 1 99 PQITLWQRPLISIKVEGQIKEALLDTGADDTVLEEMNLPGKWKPKMIGGIGGFIRVRQYEQIHIEICGKKAIGTVLIGPTPVNIIGRNILTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115983 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQKKEALLDTGADDTVLEEMNLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLIGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115986 LPV 2009 South Africa C 24 99 LDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDEVSIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115988 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVKQFDEIAIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115989 LPV 2007 South Africa C 1 99 PQITLWQRPLVTINIGGQIREALLDTGADDTVLEEIKLPGKWKPKMIGGIGGFIKVRQYDDILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115994 LPV 2009 South Africa C 1 99 PQITLWQRPLVTIRVEGQTKEALLDTGADDTVLEELDLPGRWKPKMIGGIGGFIKVRQYEQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115996 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEEIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115997 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKIEGQVKEALLDTGADDTVLEEMNLPGKWKPKMIGGIGGFIKVRQYDQIVLEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115998 LPV 2007 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEMYLPGKWKPKMIGGIGGFIKVRQYDEIPIEICGKKAIGTVLIGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116000 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116005 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQLKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116008 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEISLPGKWKPKMIGGIGGFIKVRQYEQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116010 LPV 2009 South Africa A 1 99 PQITLWQRPLVTIKIEGQLREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQVVLEICGKKAVGTVLVGPTPVNIIGRNMLTQIGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116011 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKIGGQIKEALLDTGADDTVLEEINLPGKWKPRMIGGIGGFIKVRQYEEIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116015 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQVKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAVGTVLVGDTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116016 LPV 2011 South Africa C 1 99 PQITFWQRPLVTIKVEGQLREAFLDTGADDTVLEQIDLPGKWKPKMIGGIGGFIKVKQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116019 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQTREALLDTGADDTVLENIDLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116020 LPV 2009 South Africa C 24 99 LDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116021 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116023 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEELSLPGKWKPKMIGGIGGFIKVRQYDQITIEIFGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116024 LPV 2011 South Africa CRF01_AE 1 99 PQITLWQRPIVTVKIEGQLREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVKQYDQILIDICGKKAVGTVLVGPTPVNIIGRNMLTQIGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116025 LPV 2012 South Africa C 1 99 PQITLWQRPLVTIRVGGQIKEALLDTGADDTVLEGIDLPGKWKPKMIGGIGGFIKVRQYEEVPIEISGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116026 LPV 2011 South Africa A 1 99 PQITLWQRPLVPVKVEGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYEQISIEICGKRAIGTVLVGPTPVNIIGRNMLVQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116028 LPV 2011 South Africa C 1 99 PQITLWQRPLVTIKVGGQTREALLDTGADDTVLEDMDLPGRWKPKMIGGIGGFIKVRQYDQIPMEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116029 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKIGGQTREALLDTGADDTVLEEIELPGRWKPKMIGGIGGFIKVRQYDQISIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116030 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEELSLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGKNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116031 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKIGGQIKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVKQYEQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116033 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEQILIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116034 LPV 2009 South Africa C 1 99 PQITLWQRPLVTIKVGGQIKEALLDTGADDTVLEEMSLPGKWKPKMIGGIGGFIKVRQYDQISIEICGKKAIGTVLIGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116036 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116038 LPV 2007 South Africa C 1 99 PQITLWQRPLVSIRVGGQTKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEEILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116039 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEMSLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLIGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116049 LPV 2012 South Africa C 1 99 PQITLWQRPFVSIKVGGQTRETLLDTGADDTVLEEINLPGRWKPKIIGGIGGFVKVRQYDQILIEICGKKAIGTVLVGPTPCNVIGRNMLTQLGCTLKF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116053 LPV 2011 South Africa C 1 99 PQITLWQRPLVTIKVGGQIREALLDTGADDTVLEDIELPGRWKPKMIGGIGGFIKVKQYDQILIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116054 LPV 2010 South Africa C 1 99 PQITLWQRPLVTIKIGGQLREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQVPIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116057 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKIGGQIREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116059 LPV 2011 South Africa K 1 99 PQITLWQRPFVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPANIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116060 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQTKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYEDIDIEICGKKATGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116061 LPV 2011 South Africa C 1 99 PQITLWQRPFVTIKVGGQIREALLDTGADDTVLEEINLPGKWKPKIIGGIGGFVKVRQYDHISIEICGKKVIGTVVVGPTPVNVIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116069 LPV 2007 South Africa C 1 99 PQITLWQRPLVSIKVGGQVKEALLDTGADDTVLEDLNLPGKWKPKMIGGIGGFIKVRQYDQITIEICGKKTIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116072 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLEDIDLPGKWKPRMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116074 LPV 2008 South Africa C 1 99 PQITLWQRPLVTIRVGDQIREALLDTGADDTVLEEINLSGKWKPKMIGGIGGFIKVRQYDQITIDICGKKATGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116076 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQTKEALLDTGADDTVLEEMNLPGKWKPKMIGGIGGFIKVRQYEQISIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116079 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEQILIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116082 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116086 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVEGQIKEALLDTGADDTVLEDINLPGRWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116096 LPV 2007 South Africa C 1 99 PQITLWQRPIVTIKVGGQVKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116098 LPV 2012 South Africa C 3 99 ITXWQRPLVSIKVGGQIKEALLDTGADDTVLEEIDLPGRWKPKMIGGIGGFIKVRQYDQIHIEICGKKAIGTVLVGPTPVNIIGRNILTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116100 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQTKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLIGPTPINIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116101 LPV 2011 South Africa C 1 99 PQITLWQRPLVTIKVGGQVKEALLDTGADDTVLEEMNLPGKWKPKMIGGIGGFIKVRQYDQITIEICGKKAIGSVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116103 LPV 2012 South Africa C 1 99 PQITLWQRPLVTVKIGGQTREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQITIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116104 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQVKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDEIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116106 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVGGQTREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYEEVPIEICGKKTIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116109 LPV 2012 South Africa C 1 99 PQITLWQRPLVTIKVGGQTKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDEIPIEICGKKAIGTVLVGPTPINIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116111 LPV 2008 South Africa C 22 99 ALLDTGADDTVLEEINLSGKWKPKMIGGIGGFIKVRQYEQVLIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116112 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEIDLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116118 LPV 2009 South Africa C 1 99 PQITLWQRPLVTVKIGGQTREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQITIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116122 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116124 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEEILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116126 LPV 2008 South Africa K 1 99 PQITFWQRPLVTIRVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQVPMEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116129 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQTKEALLDTGADDTVLEDIDLPGKWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116131 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVEGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIVIEICGKRAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116132 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116136 LPV 2011 South Africa C 1 99 PQITLWQRPLVTIRIGGQIKEALLDTGADDTVLEEISLPGKWKPKMIGGIGGFIKVRQYDQIAIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116138 LPV 2011 South Africa D 1 99 PQITLWQRPIVTVKIEGQLKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIQVDICGCKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116140 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQVKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116141 LPV 2007 South Africa C 1 99 PQITLWQRPLVTINVGGQRKEALLDTGADDTVLEEIDLPGKWKPKMIGGIGGFIKVRQYEEITIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116143 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEMNLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116144 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQVKEALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVKQYDQIPIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116152 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLEEIDLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116153 LPV 2010 South Africa C 1 99 PQITLWQRPLVTIKVGGQLREALLDTGADDTVLEDIDLPGRWKPKMIGGIGGFIKVKQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116164 LPV 2012 South Africa C 1 99 PQITLWQRPFVSIKVGGQTREALLDTGADDTVLEDINLPGKWKPKIIGGIGGFVKVRQYDQILIEICGKKAIGTVLVGPTPANIIGRNILTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116166 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQVIIEICGKRAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116169 LPV 2009 South Africa C 1 99 PQITLWQRPMVSIKVEGQIREALLDTGADDTVLEEINLSGKWKPKMIGGIGGFIKVRQYEQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116177 LPV 2009 South Africa C 1 99 PQITLWQRPLVTIKIGGQTREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116178 LPV 2011 South Africa C 1 99 PQITLWQRPLVTIKVGGQTREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQITIEICGKKAIGTILVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116179 LPV 2009 South Africa B 1 99 PQITLWQRPLVTIKIGGHLKEALLDTGADDTVLEDICLPGKWKPKMIGGIGGFIKVRQYDQIPIEIEGHKVMGTVLIGPTPINIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116182 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116187 LPV 2010 South Africa C 1 99 PQITLWQRPLVTIKVGGQIREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVKQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116189 LPV 2008 South Africa C 1 99 PQITLWQRPLVTIKIGGQTREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116197 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVKQYDQILIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116199 LPV 2009 South Africa C 1 99 PQITLWQRPLVTVKIEGQTKEALLDTGADDTVVEEMNLSGRWKPKMIGGIGGFIKVRQYEQIPIEICGKKAIGTVLVGPTPVNIIGRNILTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116207 LPV 2010 South Africa C 1 99 PQITLWQRPFVSVKVGGQVREALLDTGADDTVFEDINLPGKWTPKIIGGIGGFVKVRQYDHIPIEICGKRVISTVLVGPTPANIIGRNLMTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116208 LPV 2008 South Africa C 1 99 PQITLWQRPLVTIKVGGQIKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVKQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116210 LPV 2011 South Africa C 1 99 PQITLWQRPLVTIKVGGQVREALLDTGADDTVLEEIQLPGNWKPKMIGGIGGFIKVRQYNQVTIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116212 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNILTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116214 LPV 2011 South Africa C 1 99 PQITLWQRPLVTIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDEIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116217 LPV 2007 South Africa C 1 99 PQITLWQRPLVTIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQITIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116226 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEEIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116227 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVKQYDNIHIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116230 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEMNLPGKWKPKIIGGIGGFIKVRQYEQILIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116231 LPV 2007 South Africa C 1 99 PQITLWQRPIVTIKVGGQIKEALLDTGADDTVLEEISLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116232 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEMSLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116235 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQTKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116241 LPV 2009 South Africa C 1 99 PQITLWQRPIVSIKIGGQIKEALLDTGADDTVLEELNLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGKRAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116246 LPV 2012 South Africa C 1 99 PQITLWQRPLISIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVKQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116254 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIVVGGQVKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEQIPIKICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116257 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQVREALLDTGADDTVLEDLNLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116269 LPV 2009 South Africa C 1 99 PQITLWQRPLVTIKVGGQVKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116272 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVEGQTKEALLDTGADDTVLEEMSLPGRWKPKMIGGIGGFIKVKQYDQIVIEICGKKAIGTVLIGPTPINIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116274 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQTKEALLDTGADDTVLEELNLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116275 LPV 2008 South Africa C 1 99 PQITLWQRPLVTIKVGGQTKEALLDTGADDTVLEDINLPGKWKPRMIGGIGGFIKVRQYEEIPIEISGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116277 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIRVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116278 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDEIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116279 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLEDINLPGKWKPKIIGGVGGFIKVRQYDQISIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116280 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPLEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116281 LPV 2012 South Africa C 1 99 PQITLWQRPLVIIKVGGQIKEALLDTGADDTVLEEIDLPGKWKPKLIGGIGGFIKVRQYEEILIEICGKRAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116283 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQTKEALLDTGADDTVLEDIALPGKWKPKMIGGIGGFIKVRQYEEIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116289 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIAIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116292 LPV 2010 South Africa C 1 99 PQITLWQRPLVTIKVGGQLKEALLDTGADDTVLEEINLPGKWKPRMIGGIGGFIKVRQYEQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116294 LPV 2007 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116296 LPV 2007 South Africa C 1 99 PQITLWQRPIVSIKVAGQVREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFVKVRQYDQISIEICGKKAIGSVLVGPTPANIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116297 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQTREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQISIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116300 LPV 2010 South Africa C 1 99 PQITLWQRPLVTIKVGGQTREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116303 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIRIGGQIKEALLDTGADDTILEEINLPGKWKPRMAGGIGGFIKVRQYDQIPIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116305 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEMALPGKWKPKMIGGIGGFIRVRQYEQILIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116306 LPV 2011 South Africa C 1 99 PQITLWQRPFVTIKVGGQTREALLDTGADDTVLEDINLPGKWKPKIIGGIGGFVRVRQYEEVPIEICGKKVIGTVVVGPTPANIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116309 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVEGQIREALLDTGADDTVLEDINLQGKWKPKMIGGIGGFIKVRQYEEIVIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116311 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116313 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKIGGQIREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116316 LPV 2012 South Africa C 1 99 PQITLWQRPLVSVKIGGQMREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVKQYEEIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116317 LPV 2011 South Africa C 1 99 PQITLWQRPLVTIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQISIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116322 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116327 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQTKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQITIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116329 LPV 2009 South Africa C 1 99 PQITLWQRPLVTIKVGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVKQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116330 LPV 2011 South Africa C 1 99 PQITLWQRPLVTIKVGGQIKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116335 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVEGQIKEALLDTGADDTVLEEINLPGKWRPKMIGGIGGFIKVRQYDQIQIEICGKKAIGTVLIGPTPINIIGRNILTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116337 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVEGQTREALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQIAIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116338 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116339 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLEDIELPGKWKPKMIGGIGGFIKVRQYEEVTIEICEKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116341 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEITLPGKWKPRMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116343 LPV 2007 South Africa C 1 99 PQITLWQRPLVSIRVGGQIREALLDTGADDTVLEELSLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAVGTVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116352 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVGGQVMEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116356 LPV 2010 South Africa C 1 99 PQITLWQRPIVSIKVGGQIKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKALGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116362 LPV 2011 South Africa C 1 99 PQITLWQRPFVSIKVEGQIREALLDTGADDTVFEDINLPGKWKPKIIGGVGGFVKVKQYDHISIEICGKKVIGTVLVGPTPANIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116363 LPV 2012 South Africa C 1 99 PQITLWQRPLVSVRIGGQLKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116364 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLQGKWKPKMIGGIGGFIKVRQYEQVPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116365 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKIGGQIKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116368 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKIGGQVREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNILTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116369 LPV 2011 South Africa D 1 99 PQITLWQRPVVPVKIEGQLREALLDTGADDTVLEEINLPGKWKPKIIGGIGGFVKVREYDRILVEICGHKAIGTVVVGHTPANIIGRNLLTQIGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116370 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLIGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116371 LPV 2010 South Africa C 1 99 PQITLWQRPIVTIKIEGQTKEALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116376 LPV 2010 South Africa C 1 99 PQVTLWQRPIVTIKIGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPLEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116382 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVKQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116385 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVRQYDEILIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116394 LPV 2012 South Africa C 1 99 PQITLWQRPLVTIRVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116397 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVEGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116398 LPV 2011 South Africa C 1 99 PQITLWQRPLVTIKVGGQTREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116399 LPV 2006 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEDLLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEEIPIEICGKKDIGTVLVGPTPVNIIGRNILTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116400 LPV 2011 South Africa C 1 99 PQITLWQRPLVPIKIGGQTKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116404 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQTKEALLDTGADDTVLEEISLPGKWKPKMIGGIGGFIKVRQYEQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116405 LPV 2007 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116407 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEMNLPGKWKPKMIGGIGGFIKVRQYENILIEICGKKAVGAVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116411 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQVKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNILTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116413 LPV 2012 South Africa C 1 99 PQITLWQRPFVTVKIEGQIREALLDTGADDTVLEEIQLPGKWKPKIIGGIGGFVKVRQYEQITIEICGKKAIGTVVVGPTPANIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116414 LPV 2011 South Africa C 1 99 PQITLWQRPLVTIKIGGQTKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQITIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116415 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEIDLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKRAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116416 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKIEGQMKEALLDTGADDTVLEDMHLPGRWKPKMIGGIGGFIKVRQYDQICIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116417 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIRVGGQIREALLDTGADDTVLEDIDLPGKWKPKMIGGIGGFIKVRQYDQIVIEICGKKAMGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116419 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIRVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116422 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQVKEALLDTGADDTVLEEIDLPGRWKPKMIGGIGGFIKVRQYDQIVIEICGKKAVGAVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116424 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116432 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116441 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKIGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116442 LPV 2009 South Africa C 1 99 PQITLWQRPLVPIKVGDQIKEALLDTGADDTVLEEISLPGRWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116445 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVEGQIKEALLDTGADDTVLEEMNLPGKWKPRMIGGIGGFIKVRQYDQINIEICGKKAIGSVLIGLTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116448 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKIGGQIKEALLDTGADDTVLEEVNLPGRWKPKMIGGIGGFIKVRQYEQVPIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116451 LPV 2009 South Africa C 1 99 PQITLWQRPFVSIKVGGQIKEALIDTGADDTVLQEINLPGKWKPRMIGGIGGFVKVRQYDQIPIEICGKKAIGTVLVGPTPANIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116452 LPV 2008 South Africa C 1 99 PQITLWQRPLVTIRVGGQIKEAFLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116454 LPV 2010 South Africa C 1 99 PQITLWQRPFVSIKVGGQTKEALLDTGADDTVLEELQLPGRWKPKMIGGIGGFIKVRQYDQVPMEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116455 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVREYEQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116456 LPV 2011 South Africa C 1 99 PQITLWQRPLVEIKVGGQVKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEQIVIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116461 LPV 2007 South Africa C 1 99 PQITLWQRPLVSIKIGGQIREALLDTGADDTVLEEIALPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116463 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116466 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKIGGQIKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116467 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEQILIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116468 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEISLPGKWKPKMIGGIGGFIKVRQYDQITIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116475 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116478 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116479 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116482 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116485 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKIGGQTREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQITIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116488 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116491 LPV 2011 South Africa C 1 99 PQITLWQRPVVTIKIEGQLKEALLDTGADDTVLEEIQLPGKWKPKMIGGIGGFIKVRQYEQITIEICGKKAVGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116499 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEDINLPGKWKPRMIGGIGGFIKVRQYEEILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116500 LPV 2010 South Africa C 1 99 PQITLWQRPLVTIKVGGQTREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQITIEICGKKAIGTILVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116503 LPV 2012 South Africa C 1 99 PQITLWQRPLVAVKVEGQIREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIHIEICGKRAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116504 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKIGGQIKEALLDTGADDTVLEEISLPGKWKPKMIGGIGGFIKVRQYDQISIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116508 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKIGGQIREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQITIEICGKRAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116513 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVGGQTREALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVRQYDQISIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116516 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116519 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLIGPTPINIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116523 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIRVGGQIKEALLDTGADDTVLEEMSLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116525 LPV 2010 South Africa C 1 99 PQITLWQRPFVTIKIAGQIREALIDTGADDTVFEDINLPGKWKPKMIGGIGGFVKVRQYDQIPIEICGKKAIGSVLVGPTPADIVGRNILSQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116527 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVEGQIKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYEQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116528 LPV 2011 South Africa C 1 99 PQITLWQRPLVTIKVGGQTREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLIGPTPINIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116533 LPV 2009 South Africa C 1 99 PQITLWQRPLVTIKVGGQIKEAFLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDEIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116536 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116537 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116539 LPV 2007 South Africa C 1 99 PQITLWQRPLVSVRVGGQVKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEEILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116540 LPV 2008 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWIPKMIGGIGGFIKVRQYNQIPIEICGKRAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116542 LPV 2010 South Africa C 1 99 PQITLWQRPLVTIKIGGQTREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQISIEICGKKALGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116543 LPV 2009 South Africa C 1 99 PQITLWQRPMVTINIGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116544 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKIGGQIREALLDTGADDTVVEEINLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116548 LPV 2011 South Africa C 1 99 PQITLWQRPLVTINVGGQVKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEEIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116552 LPV 2012 South Africa C 1 99 PQITLWQRPIVTITVGGQVKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQITIDICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116555 LPV 2011 South Africa C 1 99 PQITLWQRPLVTIKIGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQVPIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116556 LPV 2010 South Africa C 1 99 PQITLWQRPLVTIKVGGQTREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116560 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVEGQIKEALLDTGADDTVLEDINLPGKWKPRMIGGIGGFIKVKQYDQIXIEICGKKAVGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116564 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQVREALLDTGADDTVLEDINLPGKWKPRMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116566 LPV 2008 South Africa C 1 99 PQITLWQRPVVSIKVGGQIREALLDTGADDTVLEEIDLPGRWKPKMIGGIGGFVRVKQYEQVPIEICGKKVIGTVVVGPTPANIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116568 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKIEGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEQIAIEICGKKAIGTVLVGPTPVNTIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116569 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQTKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPANIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116570 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKIEGQIKEALLDTGADDTVLEEMNLPGKWKPKMIGGIGGFIKVRQYEQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116573 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQVKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116574 LPV 2011 South Africa C 1 99 PQITLWQRPLVTITIGGQKREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDEVLIEICGKRAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116575 LPV 2011 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEDIDLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116580 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116584 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKVGGQVREALLDTGADDTVLEDIDLPGRWKPKMIEGIGGFVKVRQYDEVTIDICGKKVVGSVLVGPTPANIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116585 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKIIGGIGGFIKVRQYDQIPIEICGKKAIGTVVVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116591 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVGGQIREALLDTGADDTVLENIDLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116592 LPV 2009 South Africa C 1 99 PQITLWQRPLVTINIGGQTKEALLDTGADDTVLEDINLPGKWKPRMIGGIGGFIKVKQYEQIPIEICGKKAVGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116598 LPV 2011 South Africa C 1 99 PQITLWQRPLVTIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116599 LPV 2007 South Africa C 1 99 PQITLWQRPLVTIKVGGQVKEALLDTGADDTVLEDINLPGKWKPRMIGGIGGFIKVRQYEQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116600 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116605 LPV 2010 South Africa C 1 99 PQITLWQRPLVSIKIGGQTREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQITIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116610 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEELNLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116612 LPV 2012 South Africa C 1 99 PQITLWQRPLVSIKIGGQIKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFVKVRQYDQIPIEICGKKAIGTVLVGPTPANIIGRNMLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116615 LPV 2009 South Africa C 1 99 PQITLWQRPLVSIKIGGQTREALLDTGADDTVLEDIDLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2130 118881 LPV 2008 U.S. B 12 99 XIKIEGQLKEALLDTGADDTVLEEMNLSGRWKPKMIGGIGGFIKVRQYDQIPIEICGCKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Mollan, K 2012 23148287 J Infect Dis HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status. 2154 122313 LPV 2010 Israel C 4 99 TLWQRPLVTIKIGGQLREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122315 LPV 2004 Israel B 4 99 TLWQRPLVTIRVGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQIAIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122317 LPV 2009 Israel A 4 99 TLWQRPVVTIKIEGQLREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122318 LPV 2008 Israel C 4 99 TLWQRPILTVKIGGQLREVLLDTGADDTVLENIDLPGKWKPKIIGGIGGFVRVKQYDQVPIEICGKKVISTVLVGPTPADIIGRNVMSQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122320 LPV 2005 Israel C 4 99 TLWQRPVVSIKVGGQLREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122322 LPV 2010 Israel B 4 99 TLWQRPLVTIRIGGQLKEALLDTGADDTVVEDMYLPGRWKPKMIGGIGGFIKVRQYDQVPLEICGQKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122323 LPV 2009 Israel C 4 99 TLWQTTIITIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQITIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122324 LPV 2006 Israel C 4 99 TLWQRPVVSIKVGGQIREALLDTGADDTVLEEINLPGKWKPKIIGGIGGFVKVRQYDQIVIDICGKKVVGSVVVGPTPANIIGRNMLSQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122325 LPV 2008 Israel A 4 99 TLWQRPLVTVKIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDEIPIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122327 LPV 2008 Israel C 4 99 TLWRRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122329 LPV 2008 Israel G 4 99 TLWQRPLVTVRIGGQLIEALLDTGADDTVLEQIDLPGKWKPKMIGGIGGFIKVKQYDQISIEIEGKKAIGTVLVGPTPINIIGRNMLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122332 LPV 2009 Israel C 4 99 TLWQRPLVSIKVGGQVKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122333 LPV 2005 Israel B 4 99 TLWERPLVTVKIGGQLKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQVSVDICGHKAVGTVLVGPTPVNIIGRNLLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122335 LPV 2009 Israel C 4 99 TLWQRPLVSIRVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGSVLVGPTPVNIIGRNMLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122337 LPV 2004 Israel C 4 99 TLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122341 LPV 2010 Israel C 4 99 TLWQRPLVTIKVGGQLKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122343 LPV 2009 Israel C 4 99 TLWQRPLVAIRVGGQLKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122349 LPV 2009 Israel C 4 99 TLWQRPLVTIKVGGQLKEALLDTGVDDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILMEICGKRAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122350 LPV 2008 Israel B 4 99 TLWQRPLVTVKVGGQLKEALLDTGADDTVLEDMDLPGRWKPKMIGGIGGFIKVRQYDQVPMEICGHKAIGTVLIGPTPVNIIGRNMLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122353 LPV 2005 Israel C 4 99 TLWQRPLVSIKVGGQVKEALLDTGADDTVLEETNLPGKWKPKMIGGIGGFIKVKQYDQIAIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122354 LPV 2007 Israel C 4 99 TLWQRPLVTIKVGGQLKEALLDTGADDTVLEDINLPGKWKPRMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122356 LPV 2009 Israel C 4 99 TLWQRPLVTVRVGGQLTEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122357 LPV 2009 Israel B 4 99 TLWQRPLVAIKIGGQLKEALLDTGADDTVLEDMNLTGRWKPKMIGGIGGFIKVRQYDQVPMEICGHKVIGTVLIGPTPVNIIGRNLLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122358 LPV 2007 Israel C 4 99 TLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKRAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122359 LPV 2007 Israel C 4 99 TLWERPLVSIKVGGQVKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIIIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122361 LPV 2002 Israel B 4 99 TLWQRPIVTTKIGGQLKEALLDTGADDTVLEDMTLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGHKTIGTVLIGPTPVNIIGRDLLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122362 LPV 2006 Israel C 4 99 TLWQRPLVSIKVGGQTKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQISIEICEKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122364 LPV 2008 Israel A 4 99 TLWQRPVVTIKIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122366 LPV 2006 Israel C 4 99 TLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDHILIEICGKKAIGAVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122370 LPV 2007 Israel C 4 99 TLWQRPLVTIKIGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEQVAIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122371 LPV 2003 Israel B 9 99 PLAIIEVGGQLKEALLDTGADDTVLEDMNLPGKWKPRMIGGIGGFIKVRQYDQVPIEICGHKVIGTVLVGPTPVNIIGRNLLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122373 LPV 2009 Israel B 4 99 TLWQRPLVTIKIGGQLKEALLDTGADDTVLEDMDLPGRWKPKMIGGIGGFIKVRQYDQVSMEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122375 LPV 2009 Israel C 4 99 TLWQRPLVSIKVGGQQKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122377 LPV 2010 Israel A 4 99 TLWQRPVVTIKIGGQLKEALLDTGADDTVLEDINLPGNWKPKMIGGIGGFIKVRQYDQIPIEICGKRAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122379 LPV 2008 Israel C 4 99 TLWQRPLVSIKVEGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDNICIEICGKKAIGTVLVGPTPINIIGRNLLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122380 LPV 2005 Israel B 4 99 TLWQRPIVTIKVGGQIREALLDTGADDTVLEEIDLPGRWKPKIIGGIGGFVKVREYEQIPIEICGHKAIGTVLVGGTPTNVVGRNMLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122381 LPV 2005 Israel C 4 99 TLWQRPLVSIKVGGQVKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQITIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122382 LPV 2006 Israel C 4 99 TLWQRPLVTIKVGGQLKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQITIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122384 LPV 2006 Israel C 4 99 TLWQRPLVTVRVGGQLKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122386 LPV 2009 Israel C 4 99 TLWQRPLVTIKVGGQVKEALLDTGADDTVLEELSLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122387 LPV 2010 Israel A 4 99 TLWQRPLVTVRVGGQLKEALLDTGADDTVLEDIDLPGKWKPKMIGGIGGFIKVRQYDEILIEICGKRAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122388 LPV 2006 Israel C 4 99 TIWQRPLVTIKIEGQLKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQINIEICGKKATGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122390 LPV 2009 Israel A 4 99 TLWKRPIVTIRIGRQLKEALLDTGADDTVLEDIDLPGKWKPKMIGGIGGFIKVRQYDQILIEIYGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122391 LPV 2009 Israel A 4 99 TLWQRPLVTVKVEGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAVGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122392 LPV 2006 Israel C 4 99 TLLQRPLVTIKVGGQLKEALLDTGADDTVLEEINLSGKWKPKMVGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122396 LPV 2004 Israel F 4 99 TLWQRPLVTIKVGGQIKEALLDTGADDTVLEDINLQGKWKPKMIGGIGGFIKVKQYEDISIEICGHKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122398 LPV 2008 Israel C 4 99 TLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122401 LPV 2005 Israel C 4 99 TLWQRPLVTIKVGGQLREALLDTGADDTVLEEINLQGKWKPKMIGGIGGFIKVRQYDHILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122404 LPV 2004 Israel B 4 99 TLWQRPLVTIRIGGQIREALLDTGADDTVLEDMELPGRWKPKMIGGIGGFIKVKQYDQIPIEICGHKTIGTVLIGPTPVNIIGRNLLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122406 LPV 2003 Israel C 4 99 TLWQRPLVTIKVGGQIKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122407 LPV 2004 Israel B 4 99 TLWQRPLVTIRIGGQLKEALLDTGADDTVVEEMYLPGRWKPKMIGGIGGFIKVRQYDQVPLEICGQKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122408 LPV 2005 Israel C 4 99 TLWQRPLVSIRVGGQLKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122409 LPV 2009 Israel C 4 99 TLWQRPLVSIKIEGQIKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYEQVLIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122410 LPV 2011 Israel C 4 99 TLWQRPFVSIKVGGQIREALLDTGADDTVLEDINLPGKWKPKIIGGIGGFIRVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRDMMTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122411 LPV 2007 Israel C 4 99 TLWQRPVVTIKVGGQVREALLDTGADDTVLEEIDLPGKWKPKIIGGIGGFVRVKQYDEIPIEICGKKVIGSVVVGPTPANIIGRNMMTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122420 LPV 2009 Israel C 4 99 TLWQRPLVTIKVGGQTKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKVIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122423 LPV 2007 Israel A 4 99 TLWQRPLVTIRIGGQLKEALLDTGADDTVLEDIDLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122425 LPV 2009 Israel C 4 99 TLWQRPLVTIKVEGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQICIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122427 LPV 2009 Israel B 4 99 TLWQRPLVTIKSRGQLKEALLDTGADDTVLEELNLPGRWKPKMIGGIGGFIKVRQYDQVCIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122428 LPV 2005 Israel C 4 99 TLWQRPLVTIKVEGQLREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQVIIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122429 LPV 2006 Israel C 4 99 TLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122431 LPV 2003 Israel A 4 99 TLWQRPIVTIKIGGQLREALIDTGADDTVFEDINLPGKWKPKMIMGIGGLVKVKQYEDVPIEICGHKAIGTVLIGPTPANIIGRNLLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122432 LPV 2004 Israel C 4 99 TLWQRPLVTIRVGGQLKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122433 LPV 2003 Israel C 4 99 TLWQRPLVTIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122434 LPV 2005 Israel C 4 99 TLWQRPLVTIKVGGQLKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122435 LPV 2006 Israel A 4 99 TLWQRPLVTIRIGGQLKEALLDTGADDTVLEDIDLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122436 LPV 2011 Israel C 4 99 TLWQRPLVTIKVEGQLREALLDTGADDTVLEEINLSGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122437 LPV 2010 Israel C 4 99 TLWQRPLVTIRVGGQQKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122438 LPV 2008 Israel CRF02_AG 4 99 TLWQRPFVTVKIQGQLIEALLDTGADDTVLEEINLLGRWKPKIIGGIGGFVKVRQYDQVPIEICGKKAIGTVLVGPTPANIIGRNMLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122439 LPV 2006 Israel C 4 99 TLWQRPLVTIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122441 LPV 2005 Israel C 4 99 TLWQRPLVSIRVGGQIKEALLDTGADDTVLEEIDLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122442 LPV 2007 Israel C 4 99 TLWQRPLVTIKVEGQLREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDHISIEICGKRAIGTVLVGPTPANIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122443 LPV 2007 Israel C 4 99 TLWQRPLVTIKVGGQLKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122444 LPV 2009 Israel B 4 99 TLWQRPIVTVKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVKQYDEIQVEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122446 LPV 2010 Israel C 4 99 TLWQRPLVTIKVGGQLKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQISIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122447 LPV 2006 Israel C 4 99 TLWQRPLVTIKVGDQLREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQICIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122448 LPV 2010 Israel B 4 99 TLWQRPLVTIKIGGQLKEALLDTGADDTVLEEVNLPGRWKPKMIGGIGGFIKVRQYDQVPIDICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122449 LPV 2009 Israel C 4 99 TLWQRPLVTIKIGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122451 LPV 2004 Israel B 4 99 TLWQRPLVPVKIGGQIKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQVPLEICGHKTIGTVLVGPTPVNIIGRNLLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122455 LPV 2003 Israel A 4 99 TLWQRPLVTVKIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122458 LPV 2007 Israel A 4 99 TLWQRPLVTIRMGGQLREALLDTGADDTVLEDIDLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122459 LPV 2006 Israel C 4 99 TLWQRPLVTIRVGGQIKEALLDTGADDTVLEEIDLPGKWKPKMIGGIGGFIKVRQYDQITIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122460 LPV 2009 Israel B 4 99 TLWQRPLVAIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVKQYDQVHIEICGHKTVGTVLIGPTPVNIIGRNLLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122461 LPV 2004 Israel C 4 99 TLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122464 LPV 2007 Israel C 4 99 TLWQRPLVSVKVGGQKIEALLDTGADDTVLEEINLPGRWKPKLAGGIGGFIKVRQYDEITIEICGKKAIGSVLVGPTPVNIIGRNILTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122466 LPV 2009 Israel B 4 99 TLWQRPVVTVKIGGQLKEALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVRQYEQVQVDICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122467 LPV 2008 Israel C 4 99 TLWQRPLVSIKIGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQVTIEICGKRAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122471 LPV 2010 Israel C 4 99 TLWQRPLVTIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIVIEICGKRAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122472 LPV 2010 Israel C 4 99 TLWQRPLVSIKVGGQVKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYEEIPIEICGKRAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122474 LPV 2006 Israel C 4 99 TLWQRPLVTIKVGGQLKEALLDTGADDTVLEEINLSGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122476 LPV 2011 Israel B 4 99 TFWQRPLVTIKIGGQLKEALLDTGADDTVLEDMSLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGHKAIGTVLIGPTPVNIIGRNLLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122478 LPV 2007 Israel B 4 99 TLWQRPLVTVKIGGQLKEALLDTGADDTVLEDMNLPGKWKPKMIGGIGGFIKVKQYEQIPIDICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122481 LPV 2003 Israel C 4 99 TLWQRPLVTIKVGGQVKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIRVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122486 LPV 2010 Israel C 4 99 TLWQRPVVTIKIGGQLREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDEILIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122487 LPV 2006 Israel A 4 99 TLWQRPLVTIRVGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYEEILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122489 LPV 2005 Israel C 4 99 TLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMMTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122492 LPV 2011 Israel C 4 99 TLWQRPLVTIKVGGQLKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122493 LPV 2010 Israel C 4 99 TLWQRPLVTIKVGGQTREALLDTGADDTVLEEINLPGRWKPKIIGGIGGFVKVRQYDQILIEICGKKAIGTVLVGPTPANIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122496 LPV 2006 Israel C 4 99 TLWQRPLVTIKVGGQLKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122497 LPV 2009 Israel C 4 99 TLWQRPLVTIRVAGQIREALLDTGADDTVLEDLALPGKWKPKMIGGIGGFIKVRQYDQIMIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122501 LPV 2002 Israel C 4 99 TLWQRPFVTIKVGGQLREALIDTGADDTVLEDIDLPGKWKPKIIGGIGGFVRVRQYDQVPIEICGKKVIGTVVVGPTPANIIGRNLLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122503 LPV 2011 Israel B 4 99 TLWQRPLVTIKVGGQLKEALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVRQYDQVSIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122504 LPV 2010 Israel C 4 99 TLWQRPFVSIKVEGQIIEALLDTGADDTVLEEIDLPGKWKPKIIGGIGGFVKVRQYDQIRIEICGKKAISTVLVGPTPANIVGRNVLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122505 LPV 2009 Israel C 4 99 TLWQRPLVTIKVGGQIKEALLDTGADDTVLEELSLPGKWKPKMIGGIGGFIKVRQYDQISIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122508 LPV 2007 Israel C 4 99 TLWQRPVVTIKVEGQLREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFVKVRQYDNICIEICGKKAIGAVLVGPTPANIIGRNMLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 122509 LPV 2007 Israel C 4 99 TLWQRPLVSIKVGGQIKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 124799 LPV 2011 Israel C 4 99 TLWQRPLVTIKVGGQLKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 124800 LPV 2011 Israel A 4 99 TLWQRPIVTVRIGGQLKEALLDTGADDTVLEDIDLPGKWKPKMIGGIGGFIKVRQYEEIVIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 124805 LPV 2011 Israel B 4 99 TLWQRPIVTVKIGEQLREALLDTGADDTVLEDINLPGRWKPKMIGGIGGFIKVRQYDQVXMDICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 124808 LPV 2003 Israel CRF02_AG 4 99 TLWQRPLVTARIGGQLIEALLDTGADDTVLEEINLLGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAMGTVLVGPTPVNIIGRNILTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 124809 LPV 2008 Israel C 4 99 TLWQRPLVTIKIGEQLREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQICIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 124811 LPV 2011 Israel B 4 99 TLWQRPLVAIKIGGQLKEALLDTGADDTVVEEMYLPGRWKPKMIGGIGGFIKVRQYDQVPLEICGHKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 124812 LPV 2010 Israel C 4 99 TLWQRPFVTIKLGGQIKEALLDTGADDTVLQEIDLPGKWKPKMIGGIGGFIKVRQYDEIPIEICGKKAIGTVLVGPTPANIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 124815 LPV 2011 Israel B 4 99 TLWQRPLVTVKIGGQLKEALLDTGADDTVLEDMNLPGRWKPKMIGGIGGFIKVRQYDQVPVDICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 124817 LPV 2005 Israel A 4 99 TLWQRPLVTVKIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQITIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 124819 LPV 2011 Israel C 4 99 TLWQRPLVAIKVGGQLKEALLDTGADDTVLEEINLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGEKAIGTVLVGATPINIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 124820 LPV 2011 Israel B 4 99 TLWQRPLVTVKIGGQVKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQIAIEICGRNAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 124823 LPV 2005 Israel B 4 99 TLWQRPIVTIKIEGQLREALLDTGADDTVLEDITLSGKWKPKMIGGIGGFIKVKQYEEVPIEICGHKTIGTVLVGPTPANIIGRNLLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 124824 LPV 2011 Israel B 4 99 TLWQRPLVPIRIEGQLKEALLDTGADDTVLEDMNLPGRWKPKMIGGIGGFIKVRQYDQIHIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 124825 LPV 2006 Israel A 4 99 TLWQRPLVTVKVGGQLREALLDTGADDTVLEEIDLPGNWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 124826 LPV 2011 Israel B 4 99 TLWQRPLVTIKIGGQLKEALLDTGADDTVLEDMDLPGRWKPKMIGGIGGFIKVKQYDQVHIEICGHKTVGTVLIGPTPVNIIGRNLLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 124827 LPV 2003 Israel B 4 99 TLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDEIPIEICGHKAIGTVLIGPTPVNIIGRNLLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 124829 LPV 2008 Israel B 4 99 TLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMSLPGRWKPKMIGGIGGFIKVRQYDQVVIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 124836 LPV 2010 Israel C 4 99 TLWQRPLVTIKIGGQLKEALLDTGADDTVLEEIDLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 124839 LPV 2005 Israel B 4 99 TLWQRPFVIVKIAGQLKEALLDTGADDTVFEEMDLPGKWKPKIIGGIGGFVKVREYEQVPIEICGHKVVGTVVIGPTPANIIGRNLMTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 124840 LPV 2003 Israel C 4 99 TLWQRPLVTIRVEGQLKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVKQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 124842 LPV 2010 Israel B 4 99 TLWQRPLVAIKIGGQLKEALLDTGADDTVLEDMELPGKWKPKMIGGIGGFIKVRQYDRVDIEICGHKTTGTVLVGPTPVNIIGRNLLTQIGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2154 124844 LPV 2003 Israel B 4 99 TLWQRPLVAIKIGGQLKEALLDTGADDTVLEDMDLPGRWKPKMIGGIGGFIKVKQYDQIPIEICGHKAIGTVLIGPTPVNIIGRNLLTQLGCTLNF Grossman, Z 2014 24475093 PLoS ONE Comparable long-term efficacy of lopinavir/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. 2160 124635 LPV 2011 Nigeria CRF02_AG 1 99 PQITLWQRPLVTVRVGGQLIEALLDTGADDTVLEDINFPGKWKPKMIGGIGGFI*VRQYDQIHMEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124636 LPV 2011 Nigeria CRF02_AG 1 99 PQITLWQRPLVTVKVEGQLIEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPVEICERRAIGTVLVGPTPVNIIGRNMLTQVGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124637 LPV 2011 Nigeria G 1 99 PQITLWQRPLVQVRVGGQLIEALLDTGADDTVLEQIDLPGKWKPKMIGGIGGFIKVKQYEQILIEIEGRKAVGTVLVGPTPINIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124638 LPV 2009 Nigeria CRF02_AG 1 99 PQITLWQRPFVTVRIGGQLIEALLDTGADDTVLEDINLPGKWTPKIIMGIGGFVKVRQYDQILIEIEGRKAIGSVLVGPTPSNIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124639 LPV 2010 Nigeria CRF02_AG 1 99 PQITLWQRPVVTARVGGQLIEVLLDTGADDTVLEDINLPGKWKPKMIGGIGGFVKVRQYDHIPIEICGKKAIGTVLVGPTPANIIGRNVLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124640 LPV 2009 Nigeria CRF02_AG 1 99 PQITLWQRPFVTVRIEGQLIEALLDTGADDTVLEDINLPGKWRPKIIGGIGGFVKVRQYDQVLIEICGKKAIGEVLVGPTPANIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124641 LPV 2008 Nigeria G 1 99 PQITLWQRPLVTVRIGGQLIEALLDTGADDTVLEQIDLPGKWKPKMIGGIGGFIKVRQYDEILIEIEGRRAIGTVLVGPTPINIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124642 LPV 2011 Nigeria G 1 99 PQITLWQRPLVTVRIGGQLIEALLDTGADDTVLEQINLPGKWKPKMIGGIGGFVKVKQYDQILIEIGGEKAVGTVLVGPTPINIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124643 LPV 2008 Nigeria CRF02_AG 1 99 PQITLWQRPLVTVKIGGQLREALLDTGADDTVLEEIDLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKRAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124644 LPV 2008 Nigeria CRF02_AG 1 99 PQITLWQRPVVPVKIEGQLIEALIDTGADDTVLEAINLPGKWKPKMIVGIGGFVKVKQYDQVYIEIYGSKAIGTVLVGPTPANIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124645 LPV 2007 Nigeria G 1 99 PQITLWQRPLVTVKIGEQLIEALLDTGADDTVLEEINLPGKWKPKIIGGIGGFVKVRQYDQVLIQICGKKAIGTVLVGPTPANIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124646 LPV 2010 Nigeria G 1 99 PQITLWQRPIITVRVAGQLIEALIDTGADDTVLEQIDLPGKWKPKIVGGIGGLVRVKQYDQIPIEIEGKKVIGTVLVGPTPSNIIGRNILSQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124647 LPV 2010 Nigeria G 1 99 PQITLWQRPIVTVKVGGQLIEALLDTGADDTILEQINLPGKWKPRMAGGIGGFIKVKQYDQIPIEIEGKKVIGTVLVGPTPINIIGRNILTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124648 LPV 2011 Nigeria CRF02_AG 1 99 PQITLWQRPLVTAKIGGQLIEALLDTGADDTVLEGINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124649 LPV 2007 Nigeria CRF02_AG 1 99 PQITLWQRPLVTVRIEGQLIEALLDTGADDTVLEDINLPGKWKPKIIGGIGGFIKVRQYDHILMEICGKRAIGTVVVGPTPVNIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124650 LPV 2011 Nigeria CRF02_AG 1 99 PQITLWQRPLVTVRIEGQLIEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKRAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124651 LPV 2010 Nigeria CRF02_AG 1 99 PQITLWQRPLVAVRVGGQLIEALLDTGADDTVLEDIDLPGKWRPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124652 LPV 2009 Nigeria CRF02_AG 1 99 PQITLWQRPVVMARIAGQPIEVLLDTGADDTVLENIDLPGKWKPKMIGGIGGFVKVREYDHIPIEICGKKVIGTVLVGPTPFDIIGRNILTQMGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124653 LPV 2010 Nigeria CRF02_AG 1 99 PQITLWQRPIVTVRIGEQLIEALLDTGADDTVLEEISLPGKWKPKIIGGIGGFVKVRQYDQILIEIHGKKAIGTVLVGPTLANIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124654 LPV 2011 Nigeria G 1 99 PQITLWQRPLVTVRIGGQLIEALLDTGADDTVLEQINLPGKWKPKMIGGIGGFIKVKQYDQIPIEIEGKKAIGTVLVGPTPNNIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124655 LPV 2009 Nigeria CRF02_AG 1 99 PQITLWQRPLVTARVGGQLIEALLDTGADDTVLEEIELPGKWRPKMIGGIGGFIKVRQYDQIPIEICGKRAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124656 LPV 2011 Nigeria CRF02_AG 1 99 PQITLWQRPLVTVRIEGQLIEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILMEICGKRAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124657 LPV 2010 Nigeria A 1 99 PQITLWQRPIVTVRVGGQLIEALLDTGADDTVLEGINLPGKWKPKIVGGIGGLVRVREYDQITMEICGHKAIGTVLVGPTPANIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124658 LPV 2010 Nigeria A 1 99 PQITLWQRPLVTVKIGEQLIEALLDTGADDTVLEEINLSGRWKPKMIGGIGGFIKVRQYDQITLEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124659 LPV 2009 Nigeria CRF02_AG 1 99 PQISLWQRPVVTAKIGGQLVEVLLDTGADDTVLEDIELPGRWKPKVIGGIGGFVKVRQYDEVPIEIFGKKILGTVVVGATPMNIIGRNVMSKIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124660 LPV 2008 Nigeria G 1 99 PQITLWQRPLVTVKIGGQLLEAILDTGADDTVFDQIELPGKWKPKIIGGVGGLVKVKQYDHIPIEIEGRKAIGSVVVGPTPINIIGRNMMTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124661 LPV 2009 Nigeria CRF02_AG 1 99 PQITLWQRPLVTAKIGGQLIEALLDTGADDTVLEDIDLPGRWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124662 LPV 2011 Nigeria G 1 99 PQITLWQRPVVTVRIAGQLIEALIDTGADDTVLEDINLPGKWTPKIIGGIGGFVKVKQYDQVPIEIEGRKAVGAVLVGPTPSNIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124663 LPV 2008 Nigeria CRF02_AG 1 99 PQITLWQRPLVKVKVGGQLIEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIDICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124664 LPV 2008 Nigeria CRF02_AG 1 99 PQITLWQRPFVTVKVEGQLIEALLDTGADDTVLEDINLPGKWKPKIIGGIGGFVKVREYDQIRMEICGKRAIGTVVVGPTPANIIGRNMLAQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124665 LPV 2009 Nigeria G 1 99 PQITLWQRPVVTARVGGQLIEALLDTGADDTVLEHINLPGKWKPKLIQGIGGLVRVKQYDNILVEIEGKKAIGSVVVGPTPVNVIGRNILAQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124666 LPV 2010 Nigeria CRF02_AG 1 99 PQITLWQRPLVTVRIGEQLIEALLDTGADDTVLEEINLPGRWKPKMIGGIGGFVKVRQYDQVPIEIEGKKAIGTVLVGPTPANIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124667 LPV 2011 Nigeria G 1 99 PQITLWQRPLVTVRIGGQLIEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEISGKKAIGTVLVGPTPINIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124668 LPV 2010 Nigeria G 1 99 PQITLWQRPVVTVRIGGQLMEALLDTGADDTVFEDINLPGKWRPKMIGGIGGFIKVKQYDQILIEIEGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124669 LPV 2010 Nigeria G 1 99 PQITLWQRPLVTVRIGGQLIEALLDTGADDTVLEQIDLPGKWKPKIIGGIGGFVKVKQYDHIPIEIEGKKAIGTVLVGPTPSNIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124670 LPV 2008 Nigeria G 1 99 PQITLWQRPIVTVKVGGQIIEALLDTGADDTVLEEINLPGKWTPKLIVGIGGFVKVRQYDEILMEISGKKVIGTVLVGPTPTNIIGRNMLTQMGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124671 LPV 2009 Nigeria CRF02_AG 1 99 PQITLWQRPIVTVKIAGQLIEALLDTGADDTVLEEINLPGKWKPKIIGGIGGFVKVRQYDQILIEICGKRVIGTVVVGPTPANVIGRNVLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124672 LPV 2007 Nigeria CRF02_AG 1 99 PQITLWQRPLVTARIEGQLIEALLDTGADDTVLEEINLAGKWKPKIIGGIGGFIKVRQYDQVSIEICGKRAIGTVVVGPTPVNIIGRNILTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124673 LPV 2010 Nigeria G 1 99 PQITLWQRPLVTVRIGGQLIEALLDTGADDTVLEDIKLPGKWKPKMIGGIGGLIKVRQYDQIPIEIEGKKAIGTVLVGPTPINIIGRNMMTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124674 LPV 2010 Nigeria G 1 99 PQITLWQRPIVTVRIGEQLIEALIDTGADDTVLEQINLPGKWKPKIIGGIGGFVKVKQYDQVPIEIEGKKAIGTVLVGPTPTNIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124675 LPV 2008 Nigeria G 1 99 PQITLWQRPLVKVKIGGQLIEALLDTGADDTVLEDINLPGKWKPKVIGGIGGLVKVRQYDHILIEIEGKKAIGSVVVGPTPMNIIGRNMLAQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124676 LPV 2008 Nigeria G 1 99 PQITLWQRPMVTVRIGGQLIEALLDTGADDTVLEHINLPGKWKPKIIGGVGGFVKVKQYDHIPIEIEGKKVIGPVLVGPTPSNIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124677 LPV 2009 Nigeria CRF02_AG 1 99 PQITLWQRPLVTVRIGGQLIEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124678 LPV 2011 Nigeria CRF02_AG 1 99 PQITLWQRPIVSVRIGEQLIEALLDTGADDTVLEDISLPGKWKPKMIGGIGGFIKVRQYDQISIEICGKRAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124679 LPV 2011 Nigeria G 1 99 PQITLWQRPLVTVRIGGQLIEALLDTGADDTVLEQIDLPGRWKPKMIGGIGGFIKVKQYDQIPIEIEGKKAIGTVLVGPTPINIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124680 LPV 2010 Nigeria CRF01_AE 1 99 PQITLWQRPVVTVKIGGQLREALLDTGADDTVFENIELQGKWKPKLIVGIGGFIKVRQYEEILIEICGKKAIGTVLVGPTPVDIIGRNMMTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124681 LPV 2007 Nigeria G 1 99 PQITLWQRPMVTVRVGGQLIEALLDTGADDTVLEQINLPGKWKPKMIGGIGGFIKVKQYDQILIEIEGKKAIGTVLVGPTPINIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124682 LPV 2008 Nigeria CRF02_AG 1 99 PQITLWQRPLVTVKIEGQLIEALLDTGADDTVLEEINLPGKWRPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124683 LPV 2008 Nigeria CRF02_AG 1 99 PQITLWQRPLVTVRIGGQLIEALLDTGADDTVLEEINLPGKWKPKMIVGIGGFVKVRQYDQILIEICGKKVIGTVLVGPTPTNIIGRNVLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124684 LPV 2010 Nigeria G 1 99 PQITLWQRPIVAVRIGGQLIEALLDTGADDTVLEQIDLPGKWKPRMIGGIGGFVKVKQYDQILIEIEGKKAIGTVLVGPTPINIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124685 LPV 2010 Nigeria G 1 99 PQITLWQRPIVTVRIGGQIIEALIDTGADDTVLEQIDLPGKWKPKMIGGIGGFVKVKQYDHIPMEIEGKRAIGTVLVGPTPMNIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124686 LPV 2008 Nigeria G 1 99 PQITLWQRPLVTVRIGGQLIEALLDTGADDTVLEQIDLPGKWKPKMIGGIGGFIKVKQYDQIPIEIEGKKAIGTVLVGPTPINIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124687 LPV 2011 Nigeria CRF02_AG 1 99 PQITLWQRPLVTVRIGGQLIEALLDTGADDTVLEQIDLPGKWKPKMIGGIGGFIKVKQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124688 LPV 2010 Nigeria G 1 99 PQITLWQRPLVKVRIGGQIIEALLDTGADDTVLEQIDLPGKWKPKMIGGIGGFIKVKQYDHILIEIEGKRAIGTVLVGPTPINIIGRNMLTQIGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2160 124689 LPV 2010 Nigeria C 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGSVLIGPTPVNIIGRNMLTQLGCTLNF Rawizza, HE 2013 24069209 PLoS ONE Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. 2164 125809 LPV 2009 Senegal A 1 99 PQITLWQRPIITVKIGGQPIEALLDTGADDTVLEDINLPGKWKPKIIGGIGGFIKVRQYDQVLIEICGKRVRGTVVVGSTPVNVIGRNVLSKIGCTLNF Thiam, M 2013 23241378 J Clin Microbiol HIV-1 genetic diversity and drug resistance among Senegalese patients in the public health system. 2164 125810 LPV 2011 Senegal CRF02_AG 1 99 PQITLWQRPIVTVKIEGQLIEALLDTGADDTVLEEINLPGKWKPKIIGGIGGFVKVREYDQIRIEICGKRAVGTVVVGPTPVNVIGRNMLTQIGCTLNF Thiam, M 2013 23241378 J Clin Microbiol HIV-1 genetic diversity and drug resistance among Senegalese patients in the public health system. 2164 125811 LPV 2009 Senegal D 1 99 PQITLWQRPVVTVKIGGQLKEALLDTGADDTVIEDINLPGKWKPVMIGGIGGFAKVRQYDQVDVEICGHKATGTVLVGPTPFNIIGRNLLTQIGCTLNF Thiam, M 2013 23241378 J Clin Microbiol HIV-1 genetic diversity and drug resistance among Senegalese patients in the public health system. 2164 125812 LPV 2009 Senegal CRF02_AG 1 99 PQITLWQRPIITVKIGGQPIEVLLDTGADDTVLEEISLPGKWKPKIVGGIGGLVKVRQYDHILIEICGKKVIGTVLVGPTPANVIGRNILSQIGCTLNF Thiam, M 2013 23241378 J Clin Microbiol HIV-1 genetic diversity and drug resistance among Senegalese patients in the public health system. 2164 125813 LPV 2008 Senegal CRF02_AG 1 99 PQITLWQRPLVTVRIGGQLIEALLDTGADDTVLEEIELPGRWKPKIIGGIGGFIKVRQYDQIPLEICGKRAIGTVVVGPTPVNIIGRNMLTQIGCTLNF Thiam, M 2013 23241378 J Clin Microbiol HIV-1 genetic diversity and drug resistance among Senegalese patients in the public health system. 2164 125814 LPV 2010 Senegal CRF02_AG 1 99 PQISLWQRPIVMAMIGGQPIEVLLDTGADDTVIEDIDLPGKWKPKIVGGIGGFVKVKQYDHVPIEFCGKKVIGTVLVGPTPVNVIGRNVMTQIGCTLNF Thiam, M 2013 23241378 J Clin Microbiol HIV-1 genetic diversity and drug resistance among Senegalese patients in the public health system. 2164 125815 LPV 2011 Senegal CRF02_AG 1 99 PQITLWQRPFITVKIEGQPIEVLLDTGADDTVLEEINLPGKWKPKIIGGIGGFIKVRQYDQIRIEICGKRAIGTVVVGPTPVNVIGRNILAQIGCTLNF Thiam, M 2013 23241378 J Clin Microbiol HIV-1 genetic diversity and drug resistance among Senegalese patients in the public health system. 2169 126199 LPV 2008 Kenya A 13 99 IRIEGQLREALLDTGADDTVLEDINLPGKWKPRMIGGIGGFIKVKQYDQVVIEICGKKAVGTVLVGPTPVNIIGRNMLTQIGCTLNF Inzaule, S 2013 23224100 J Clin Microbiol Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. 2169 126202 LPV 2007 Kenya A 13 99 VRIGGQLKEALLDTGADDTVLEDIDLPGKWKPKMIGGIGGFIKVKQYEQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Inzaule, S 2013 23224100 J Clin Microbiol Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. 2169 126203 LPV 2007 Kenya D 13 99 VRIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVKQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Inzaule, S 2013 23224100 J Clin Microbiol Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. 2169 126207 LPV 2007 Kenya A 13 99 VKIEGQLREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVKQYDQITIDICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Inzaule, S 2013 23224100 J Clin Microbiol Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. 2170 126257 LPV 2010 South Africa C 1 99 PQITLWQRPLVTIKVEGQLKEALLDTGADDTVLEELNLPGRWKPKMIGGIGGFIKVRQYDQIAIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2178 127996 LPV 2008 Cambodia CRF01_AE 1 99 PQITLWQRPFVTVKIGGQLKEALLDTGADDTILEEINLPGKWKPKMAGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNILTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128003 LPV 2010 Cambodia CRF01_AE 1 99 PQITLWQRPLVTVKIEGQLREALLDTGADDTVLEDINLPGKWKPKIIGGIGGFVKVRQYDQILIEICGKRAIGTVLVGPTPANIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128004 LPV 2009 Cambodia CRF01_AE 1 99 PQITLWQRPLVTVKIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPINIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128010 LPV 2009 Cambodia CRF01_AE 1 99 PQITLWQRPVVTIKIEGQLREALLDTGADDTVLEDVNLSGKWKPKIIGGIGGFVRVRQYDQVPIEICGKKVIGTVLVGPTPANIIGRNLMTQLGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128012 LPV 2007 Cambodia CRF01_AE 1 99 PQITLWQRPLVTVKIGGQLKEALLDTGADDTVVEDINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128018 LPV 2007 Cambodia CRF01_AE 1 99 PQITLWQRPRVTARIGGQLIEALLDTGADDTVLEDIDLPGKWKPKIIVGIGGFVNVRQYEQIPIEICGKRVIGTVVVGPTPTNIIGRNVLAKIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128021 LPV 2009 Cambodia CRF01_AE 1 99 PQITLRQRPLVTIKIGGRLREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKRAEGTVLEGPAPVNIIGRNIWPQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128022 LPV 2007 Cambodia CRF01_AE 1 99 PQITLWQRPIVTVKIEGQLKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNILTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128025 LPV 2009 Cambodia CRF01_AE 1 99 PQITLWQRPFVTVKIAGQIKEALLDTGADDTVIEDIDLPGKWKPKIAGGIGGLIKVKQYDNIPIEIFGKRAIGTVLVGPTPVNVIGRNIMVQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128027 LPV 2006 Cambodia CRF01_AE 1 99 PQITLWQRPVVTVKIEGQLREALLDTGADDTVFEDIDLPGKWKPKMIGGIGGFVKVRQYDQICIEICGKKAIGPVLVGPTPANIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128029 LPV 2006 Cambodia CRF01_AE 1 99 PQITLWQRPLVTVKIGGQLKKALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGQNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128030 LPV 2006 Cambodia CRF01_AE 1 99 PQITLWQRPIVTVKIGGQLREALIDTGADDTVIEDIELPGRWKPKIIGGIGGFVRVKEYDQVPIEICGKKAIGSVLVGPTPSNIIGRNVLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128032 LPV 2009 Cambodia CRF01_AE 1 99 PQITLWQRPLVTVKIGGQLKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPINIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128034 LPV 2009 Cambodia CRF01_AE 1 99 PQITLWQRPIVAVKIEGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVKQYDQILIEICGKRAVGTVLVGPTPVNIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128035 LPV 2005 Cambodia CRF01_AE 1 99 PQITLWQRPLVTVKIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTALVGPTPVNIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128038 LPV 2010 Cambodia CRF01_AE 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128043 LPV 2009 Cambodia CRF01_AE 1 99 PQITLWQRPLVTVKVGGQLKEALLDTGADDTVLEDIDLPGKWKPKMIGGIGGFIKVRQYEQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128044 LPV 2010 Cambodia CRF01_AE 1 99 PQITLWQRPIVTVKIEGQLIEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQICIEICGERAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128046 LPV 2008 Cambodia CRF01_AE 1 99 PQITLWQRPLVAVKIGGQLIEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKRAIGTVLVGPTPINIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128047 LPV 2009 Cambodia CRF01_AE 1 99 PQIPLWQRPFITVRIGGQLREVLLDTGADDTVIESINLPGKWKPKLIGGIGGFVKVREYEQVPIEICGKKVIGTVLVGPTPVDVIGRNVLGEIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128048 LPV 2010 Cambodia CRF01_AE 1 99 PQISLWQRPILTVKIGGQLIEALLDTGADDTVLEDINLPGRWKPKMIVGIGGFVKVRQYDQVPIEICGKKTIGTVLVGPTPANIIGRNVLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128053 LPV 2009 Cambodia CRF01_AE 1 99 PQITLWQRPIVTVKIAGQLKEALLDTGADDTVFEEINLPGKWKPKIIGGVGGFVKVRQYDQIVIEICGKRAIGPVLVGPTPANIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128057 LPV 2010 Cambodia CRF01_AE 1 99 PQITLWQRPFVTVKIGGQLTEALLDTGADDTVFEDINLPGKWKPKIIGGIGGLIRVKEYDQIPIEFCGKKVISTVLVGPTPVNVIGRGVMTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128058 LPV 2006 Cambodia CRF01_AE 1 99 PQITFWQRPLVTIKIGGQLKEALLDTGADDTVLENINLPGKWKPKMIGGIGGFVKVRQYDQICIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128059 LPV 2010 Cambodia CRF01_AE 1 99 PQITLWQRPLVTVKIEGQLIEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVKQYEQILIEICGKRAVGTVLVGPTPVNIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128061 LPV 2006 Cambodia CRF01_AE 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128062 LPV 2009 Cambodia CRF01_AE 1 99 PQITLWQRPIVPVKIEGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQITIEICGKRAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128067 LPV 2009 Cambodia CRF01_AE 1 99 PQITLWQRPIVAVKIEGQLKEALLDTGADDTVLEDIDLPGKWKPKMIGGIGGFIKVKQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128070 LPV 2010 Cambodia CRF01_AE 1 99 PQITLWQRPVVTIKIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVKQYDQVCIEICGKKAIGSVLVGPTPVNIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128071 LPV 2006 Cambodia CRF01_AE 1 99 PQITLWQRPLVTIKIGGQLREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128074 LPV 2010 Cambodia CRF01_AE 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQICIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128077 LPV 2009 Cambodia CRF01_AE 1 99 PQITLWQRPLVTVKIGGQLKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128080 LPV 2006 Cambodia CRF01_AE 1 99 PQIIFWQGPLVPVKIEGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128081 LPV 2007 Cambodia CRF01_AE 1 99 PQITLWQRPFVTVKIQGQVIEALLDTGADDTVLEDINLSGKWKPKIVGGIGGFIRVRQYEQILIEFCGKKVIGTVVVGPTPVNVIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128086 LPV 2010 Cambodia CRF01_AE 1 99 PQITLWQRPLVTIKIGGQLREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQICIEICEKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128087 LPV 2010 Cambodia CRF01_AE 1 99 PQITLWQRPFVTVKIEGQLIEALLDTGADDTVLEDIDLPGKWTPKMIGGIGGFVKVRQYDHIRIEICGKKTIGTVLVGPTPANIIGRNVMSQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128088 LPV 2009 Cambodia CRF01_AE 1 99 PQITLWQRPLVTVKIGGQLKEALLDTGADDTVFEEMNLPGKWRPKMIGGIGGFIKVRQYDQIIVEICGKRAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128092 LPV 2007 Cambodia CRF01_AE 1 99 PQITLWQRPLVTVKIGEQLIEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVKQYDQILIEICGRRAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128093 LPV 2008 Cambodia CRF01_AE 1 99 PQITLWQRPIVTVKVGGQLIEALLDTGADDTVLEDINLPGKWKPKIIGGIGGLIRVRQYEQIPIEFCGKRAIGTVVVGPTPVNVIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128095 LPV 2009 Cambodia CRF01_AE 1 99 PQITLWQRPVVTVKIEGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQITIEICGKRAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128099 LPV 2009 Cambodia CRF01_AE 1 99 PQITLWQRPFVPVKIEGQLREALLDTGADDTVLEDINLPGKWKPIMIGGIGGFVKVRQYDQITIEICGKKAIGTVLVGPTPANIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128100 LPV 2007 Cambodia CRF01_AE 1 99 PQITLWQRPFVTVKIEGQLKKALLDTGADDTVLEDINLPGKWKPKIIGGIGGFIKVRQYDQILIEICGKKARGTVVVGPTPVNVIGRNILTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128101 LPV 2008 Cambodia CRF01_AE 1 99 PQITLWQRPVVTIKIGGQLIEALLDTGADDTVLEDINLPGKWKPKIIGGIGGFVKVRQYDHVCIEICGKKAIGSVLVGPTPFNIIGRNIMTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128102 LPV 2008 Cambodia CRF01_AE 1 99 PQITLWQRPLVTVKIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVKQYDQILIEICGKKAIGTVLVGPTPINIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128105 LPV 2008 Cambodia CRF01_AE 1 99 PQITLWQRPIVTVKIGGQLKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTKIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128106 LPV 2009 Cambodia CRF01_AE 1 99 PQITLWQRPIVTVKIEGQLIEALLDTGADDTVLENIDLPGRWKPKIVGGIGGFIRVREYDQITVEICGKKATGTVVVGPTPFNIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128107 LPV 2008 Cambodia CRF01_AE 1 99 PQITLWQRPIVTVKIGGQLKEALLDTGADDTVLEDIDLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKRAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128109 LPV 2008 Cambodia CRF01_AE 1 99 PQITLWQRPVVTVKIEGQLREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQICIEICGKKAIGAVLVGPTPANIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128112 LPV 2010 Cambodia CRF01_AE 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQICIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128113 LPV 2009 Cambodia CRF01_AE 1 99 PQITLWQRPLVTVKVGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQICIEICGKKAIGTVLVGPTLVNIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128118 LPV 2010 Cambodia CRF02_AG 1 99 PQITLWQRPFLTVKIGGQVVEALLDTGADDTVIEDIDLPGKWTPKIIGGIGGFVRVRQYDQIPIEICGKTVIGSVLVGPTPANIIGRDTMAQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128123 LPV 2010 Cambodia CRF01_AE 1 99 PQITLWQRPLVTVKIGGQLREALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQILVEICGKKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128130 LPV 2007 Cambodia CRF01_AE 1 99 PQITLWQRPFVTVKIGGQLREVLLDTGADDTVLEEIDLPGKWKPKMIGGIGGFVKVRQYDQIPIEICGKKAIGTVLVGPTPADIIGRNILAQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128133 LPV 2009 Cambodia CRF01_AE 1 99 PQITLWQRPFVTIKIGGQLIEALIDTGADDTVLENINLPGRWKPKIVGGIGGFVRVRQYDQVPIEICGKKVIGAVLVGPTPVNVIGRNMLTQLGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128134 LPV 2010 Cambodia CRF01_AE 1 99 PQITLWQRPVVTAKIEGQLIEALLDTGADDTVIEDIHLSGKWKPKIVGGIGGLIRVREYEHVLIEFCGKRVIGTVVVGPTPVNVIGRNVLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128135 LPV 2008 Cambodia CRF01_AE 1 99 PQITLWQRPLVTIKIGGELKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128138 LPV 2009 Cambodia CRF01_AE 1 99 PQITLWQRPLVTIKIKGQLKKALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQIFIEICGKKAIGTVLVGPTPVNIIGQNMLTQLGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128141 LPV 2008 Cambodia CRF01_AE 1 99 PQITLWQRPIVTAKIGGQLIEALLDTGADDTVLEEINLPGKWKPKLVVGIGGLVKVRQYDQIPIEFCGKKVIGTVLVGPTPTNVIGRNVLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128143 LPV 2010 Cambodia CRF01_AE 1 99 PQITLWQRPVVTVKIAGQLKEALLDTGADDTIFEEIDLPGKWKPKIVGGIGGFMRVREYNQIPVEICGKRVIDTVLVGPTPVDIIGRNIMTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128146 LPV 2009 Cambodia CRF01_AE 1 99 PQITLWQRPLVTVKIEGQLREALLDTGADDTVLEDINLSGKWKPRMIGGIGGFIKVKQYDQILIEICGKRAVGTVLIGPTPVNIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128147 LPV 2009 Cambodia CRF01_AE 1 99 PQITLWQRPLVTVKIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128148 LPV 2009 Cambodia CRF01_AE 1 99 PQITLWQRPVVTVKIEGQLTEALLDTGADDTVLEEINLPRKWKPKIIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128150 LPV 2006 Cambodia CRF01_AE 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVKQYDQILIEICGKKAIGTVLVGPTPVNIIGQNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128154 LPV 2009 Cambodia CRF01_AE 1 99 PQITLWQRPIVTVKIEGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQVTIDICGKKAIGSVLVGPTPVNIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128155 LPV 2008 Cambodia CRF01_AE 1 99 PQITLWQRPLVTIKIEGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYEQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128157 LPV 2010 Cambodia CRF01_AE 1 99 PQITLWQRPVVTAKIGGQLIEALLDTGADDTVLEEINLPGRWKPKIAGGIGGFIRVRQYDQIPIEICGKKVIGTVLVGPTPVNVIGRNVMTQMGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128160 LPV 2009 Cambodia CRF01_AE 1 99 PQITLWQRPLVTVKIGGQLIEALLDTGADDTVLEEIDLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128161 LPV 2010 Cambodia CRF01_AE 1 99 PQITLWQRPIVTVKIEGQLREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQITIEICGKKAIGAVLVGPTPANIIGRNMLTQVGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128164 LPV 2010 Cambodia CRF01_AE 1 99 PQITLWQRPLVTVKIRGQLKEALLDTGADDIVLEEINLPGKWKPKVIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIACTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128165 LPV 2009 Cambodia CRF01_AE 1 99 PQITLWQRPFVTVKIGGQLKEALLDTGADDTVIEDINLPGRWKPKIIGGIGGFVKVREYDQILIEICGKRAIGTVLVGPTPANIIGRNILTQIGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2178 128166 LPV 2009 Cambodia CRF01_AE 1 99 PQITLWQRPIVTIKIGGQLKEALLDTGADDTVLEDINLPGKWKPRMIGGIGGFIKVRQYDQIQIEICGKKAIGTVLVGPTPVNIIGRNMLTQMGCTLNF Nerrienet, E 2014 unpublished HIV-1 protease inhibitors resistance profiles patients virological failure LPV/r based 2nd line regimen Cambodia. 2187 131429 LPV 2011 Russia A 1 99 PQITLWQRPIVTVRIEGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQITIDICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131431 LPV 2013 Russia A 1 99 PQITLWQRPLVTVRIGGQLKKALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLIGPTPVNIIGKNMLTQIGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131440 LPV 2011 Russia A 1 99 PQITLWQRPIVTIRIEGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDEIIIEICGQKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131445 LPV 2010 Russia A 1 99 PQITLWQRPIVTVKIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDEITIDICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131446 LPV 2012 Russia A 1 99 PQITLWQGLLVTIRIAGQLKEALLDTGADDTVLEDIDLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131456 LPV 2011 Russia A 1 99 PQITLWQRPLVTVRIGGQLREALLDTGADDTVLEDIDLPGKWKPKMIGGIGGFIKVKQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131457 LPV 2012 Russia A 1 99 PQITLWQRPIVTVRIEGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131459 LPV 2010 Russia A 1 99 PQITLWQRPLVTVKIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLIGPTPVNIIGRNMLTQIGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131461 LPV 2013 Russia A 1 99 PQITLWQRPIVTVRIEGQLKEALLDTGADDTVLEDIDLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLIGPTPVNIIGRNMLTQIGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131462 LPV 2010 Russia A 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131463 LPV 2013 Russia A 1 99 PQITLWQRPVVTVKVGGQLIEALLDTGADDTVLKNIDLPGKWKPKMIGGIGGFIRVRQYDQILIEICGKKAIGTVLIGPTPVNIIGRNMLTQIGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131466 LPV 2011 Russia A 1 99 PQITLWQRPLVTVRIEGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131467 LPV 2012 Russia A 1 99 PQITLWQRPVVTIKIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131470 LPV 2012 Russia A 1 99 PQITLWQRPIVTVRIEGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLIGPTPVNIIGRNMLTQIGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131480 LPV 2013 Russia CRF02_AG 1 99 PQITLWQRPLVTVRIEGQLIEALLDTGADDTVLEDIDLPGKWKPKMIGGIGGFIKVRQYDQILMEIYGKRAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131485 LPV 2012 Russia A 1 99 PQITLWQRPIVTVRIEGQLKEALLDTGADDTVLENINLPGKWKPKMIGGIGGFIKVRQYDQVLIEICGKKAIGSVLIGPTPVNIIGRNMLTQIGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131486 LPV 2012 Russia CRF02_AG 1 99 PQITLWQRPLVTVRIEGQLIEALLDTGADDTVLEDIDLPGKWKPKMIGGIGGFIKVRQYDQILMEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131494 LPV 2011 Russia A 1 99 PQITLWQRPLVTVKIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131496 LPV 2011 Russia A 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEDINLPGKWKPKIIGGIGGFVKVRQYDQIIIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131502 LPV 2011 Russia A 1 99 PQITLWQRPLVTVRIEGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLIGPTPVNIIGRNMLTQIGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131505 LPV 2011 Russia A 1 99 PQITLWQRPLVTVRVVGQLKEALLDTGADDAVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131507 LPV 2011 Russia A 1 99 PQITLWQRPLVTVRIEGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLIGPTPVNIIGRNILTQLGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131515 LPV 2012 Russia A 1 99 PQITLWQRPLVTIRIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131517 LPV 2011 Russia A 1 99 PQITLWQRPIVTVKIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVKQYDEITLDICGKKAIGTVLIGPTPVNIIGRNMLTQIGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131518 LPV 2011 Russia A 1 99 PQITLWQRPLVTVKIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVKQYDQILIENCGKKAIGTVLIGPTPVNIIGRNMLTQIGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131520 LPV 2012 Russia A 1 99 PQITLWQPPIVTIRIEGQLKEALLDTGADDTVLEEINLPGKGKPKMIGGIGGFIKVRQYDQILIEICGQKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131521 LPV 2010 Russia A 1 99 PQITLWQRPLVTVRIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131526 LPV 2012 Russia A 1 99 PQITLWQRPLVTVRIEGQLIEALLDTGADDTVLENIYLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKRAIGTVLIGPTPVNIIGRNMLTQIGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131533 LPV 2013 Russia A 1 99 PQITLWQRPLVTVKVGGQLREALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDEISIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131541 LPV 2013 Russia A 1 99 PQITLWQRPLVTVRIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131544 LPV 2013 Russia A 1 99 PQITLWQRPLVTIRIEGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQVPIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131550 LPV 2012 Russia A 1 99 PQITLWQRPIVTVKVGGQLKEALLDTGADDTVLEDIDLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLIGPTPVNIIGRNMLTQIGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131554 LPV 2012 Russia A 1 99 PQITLWQRPLVTVKIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLIGPTPVNIIGRNMLTQIGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131558 LPV 2012 Russia A 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDEIPIEIFGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131559 LPV 2012 Russia A 1 99 PQITLWQRPLVTVRIEGQIIEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLIGPTPVNIIGRNMLTQIGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131568 LPV 2011 Russia A 1 99 PQVTLWQRPIVTVKVGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQVLIEICGKKAIGTVLIGPTPVNIIGRNMLTQIGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131575 LPV 2011 Russia A 1 99 PQITLWQRPLVTVKIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLIGPTPVNIIGRNMLTQIGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131576 LPV 2012 Russia A 1 99 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEDKNLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLIGPTPVNIIGRNMLTQIGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131579 LPV 2011 Russia A 1 99 PQITLWQRPLVTIRIEGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131580 LPV 2012 Russia CRF02_AG 1 99 PQITLWQRPLVTIRIEGQLIEALLDTGADDTVLENIDLPGKWKPKMIGGIGGFIKVRQYDQILMEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131581 LPV 2012 Russia CRF02_AG 1 99 PQVTLWQRPLVTVRIEGQLIEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILMEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131592 LPV 2012 Russia A 1 99 PQITLWQRPLVTIKIEGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKRAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131597 LPV 2011 Russia A 1 99 PQITLWQRPLVTIKIEGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYEEVLIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131603 LPV 2011 Russia A 1 99 PQITLWQRPLVTVKVGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131606 LPV 2011 Russia A 1 99 PQITLWQRPLVTVKVGGQLKEALLDTGADDTVLEEINLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131608 LPV 2012 Russia A 1 99 PQITLWQRPLVTIKIEGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131618 LPV 2013 Russia A 1 99 PQITLWQRPLVTVKIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQITIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131619 LPV 2012 Russia A 1 99 PQITLWQRPIVSVRIGGQLKEALLDTGADDTVLEDINLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLIGPTPVNIIGRNMLTQIGCTLNF Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2191 135092 LPV 2012 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQITIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135093 LPV 2011 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQVVLEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135094 LPV 2012 South Africa C 39 99 PGKWKPKIIGGIGGFVKVKQYDHVVIEICGKKVIGSVLVGPTPSNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135095 LPV 2012 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYEEIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135096 LPV 2011 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135100 LPV 2011 South Africa C 39 99 PGKWKPKMIGGVGGFVKVRQYDQILIEICGKKVIGSVLVGPTPANIIGRNILTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135102 LPV 2009 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135105 LPV 2010 South Africa C 39 99 PGKWKPKMIGGIGGFIKVKQYEQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135119 LPV 2010 South Africa C 39 99 PGKWKPKMIGGIGGFIKVKQYEQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135123 LPV 2012 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYEQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135124 LPV 2012 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDEILIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135130 LPV 2010 South Africa A 39 99 PGKWKPKIIGGIGGFVKVRQYDQIPIEICGKKVIGTVLVGPTPANIIGRNLLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135136 LPV 2009 South Africa A 39 99 PGKWKPKIIGGIGGFVKVREYEQVPIEICGKKAIGTVVVGPTPANIIGRNILTQIGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135137 LPV 2009 South Africa C 39 99 PGKWRPKIIGGIGGFVKVRQYDQIVIEICGKKAIGSVLVGPTPANIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135138 LPV 2012 South Africa C 39 99 PGRWKPKIIGGIGGFVKVRQYDHVPIEICGKKAIGTVVVGPTPANIIGRNILSQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135139 LPV 2010 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQISIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135142 LPV 2011 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQITLEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135144 LPV 2012 South Africa C 39 99 PGKWKPKIIGGIGGFVRVKQYDQVPIEICGKKAIGTVVVGPTPANIIGRNILTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135157 LPV 2009 South Africa C 39 99 PGKWKPIMIGGIGGFVKVRQYEDITIEICGKKAIGTVLVGPTPANIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135161 LPV 2011 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQIVIDICGKRAIGTVLIGPTPINIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135164 LPV 2011 South Africa C 39 99 PGRWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135165 LPV 2012 South Africa F 39 99 PGKWKPRMIGGIGGFIKVRQYDQIPIEIYGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135167 LPV 2012 South Africa C 39 99 PGKWKPKIIGGIGGFVKVRQYDQIPIEICGKKVIGTVVVGPTPANIIGRNLLTRLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135168 LPV 2012 South Africa C 39 99 PGKWKPKMIGGIGGFIKVKQYEQILIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135173 LPV 2011 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135179 LPV 2011 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135182 LPV 2011 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQIRIEICGKQAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135186 LPV 2012 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135187 LPV 2011 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQIHIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135189 LPV 2012 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQITIEICGKKAVGSILVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135191 LPV 2010 South Africa C 39 99 PGKWKPKIIGGIGGFVKVRQYDRIPIEICGKKVIGTVVVGPTPANVIGRNLLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135193 LPV 2011 South Africa C 39 99 PGKWKPKMIGGIGGFIKVREYDEIPIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135195 LPV 2011 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDNILIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135205 LPV 2012 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135208 LPV 2012 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135216 LPV 2010 South Africa CRF02_AG 39 99 PGKWKPKMIGGIGGFIKVRQYEEILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135217 LPV 2012 South Africa F 39 99 SGKWKPKMIGGIGGFIKVKQYDQITIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135218 LPV 2012 South Africa C 40 99 GKWKPRMIGGIGGFIKVRQYEEIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135219 LPV 2012 South Africa C 39 99 PGKWKPKMAGGIGGFIKVKQYDQIPIEICGQKVIGTVLVGPTPANIIGRNLLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135220 LPV 2012 South Africa K 39 99 PGRWKPKIIGGIGGFVKVRQYDQVVIEICGKKAIGSVVVGPTPANIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135221 LPV 2011 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135223 LPV 2011 South Africa C 39 99 PGKWKPKIIGGIGGFVKVRQYDQIPIEICGKKAIGSVLVGPTPANIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135224 LPV 2011 South Africa C 39 99 PGKWKPKLAGGIGGFIKVRQYDQIPIEICGQKAVGTVLVGPTPVNVIGRNLLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135227 LPV 2011 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135229 LPV 2010 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQISIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135230 LPV 2012 South Africa CRF02_AG 39 99 PGKWKPKMIGGIGGFIKVKQYEEILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135231 LPV 2012 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135235 LPV 2011 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135238 LPV 2010 South Africa C 39 99 PGKWKPKMIGGIGGFVKVRQYDQIPIEICGKKAIGTVLIGPTPANIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135240 LPV 2010 South Africa C 39 99 PGKWKPRMIGGIGGFIKVRQYDQILIEICGKKAIGAVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135247 LPV 2011 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135254 LPV 2012 South Africa C 39 99 PGKWKPRMIGGIGGFIKVRQYDQITIEICGKKAIGSVLVGPTPANIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135256 LPV 2012 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135258 LPV 2012 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQISIEICGKKAIGSVLIGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135259 LPV 2012 South Africa A 39 99 PGRWKPKIIGGIGGFVKVRQYDHVVIEICGKKAIGSVVVGPTPANIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135264 LPV 2012 South Africa C 39 99 PGKWKPKMIGGIGGFVKVRQYDHIPIEICGKKVIGTVVVGPTPANIIGRNLLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135268 LPV 2010 South Africa A 39 99 PGKWKPKIIGGIGGFVKVRQYDQIPIEICGKKVIGTVLVGPTPANIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135270 LPV 2011 South Africa C 39 99 PGRWKPKLIGGIGGFVKVRQYEQIPIEICGKKAIGTVLVGPTPANIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135287 LPV 2009 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQIHIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135288 LPV 2009 South Africa C 40 99 GRWKPKIIGGIGXFVKVRQYEGILIEICGNKVIGTVVVGPTPVNVIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135289 LPV 2012 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQIIIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135290 LPV 2010 South Africa C 39 99 PGKWKPKIIGGIGGFVKVRQYDQVPIEICGKKVVGTVVVGPTPANIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135291 LPV 2012 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135292 LPV 2012 South Africa C 39 99 PGKWKPKIIGGIGGFVKVRQYDHILIEICGKKAIGTVLVGPTPANIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135320 LPV 2012 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135323 LPV 2012 South Africa C 39 99 PGRWKPKIIGGIGGFVKVREYEQIPIEICGKKAIGTVLVGPTPANIIGRNMLTKLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135324 LPV 2011 South Africa C 39 99 PGKWKPKMIGGIGGLVKVRQYEHIPIEICGKKVIGTVVVGPTPANIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135328 LPV 2011 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYEEILIEICGKKAIGTVLVGPTPINIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135329 LPV 2010 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQVHIEICGKKTIGTVLVGPTPVNIIGRNLLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135332 LPV 2011 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYEEVPIEICGKKAMGTVLIGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135338 LPV 2012 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYEQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135343 LPV 2012 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135348 LPV 2011 South Africa C 39 99 PGKWKPKMIGGIGGFIKVKQYDQIPIEICGKKAIGSVLVGPTPINIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135351 LPV 2009 South Africa A 39 99 PGKWKPKIIGGIGGFVKVRQYEEIPIEICGKKAIGTVVVGPTPANIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135356 LPV 2012 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135357 LPV 2010 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQIHIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135360 LPV 2009 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYENILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135362 LPV 2011 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135364 LPV 2011 South Africa C 39 99 PGKWKPRLAGGIGGFIKVRQYDQIPIEICGQKAVGTVLVGPTPINVIGRNLLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135365 LPV 2012 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDEVVLDICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135369 LPV 2011 South Africa C 39 99 PGKWKPKMIGGIGGFVKVRQYDQIPIEICGKKAIGTVLVGPTPANIIGRNLLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135373 LPV 2011 South Africa A 39 99 PGKWKPKMIGGIGGFIKVRQYDQILIEICGKRAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135376 LPV 2012 South Africa C 39 99 PGKWKPRMIGGIGGFIKVRQYDQIVIEICGKKAIGSVLIGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135377 LPV 2012 South Africa C 39 99 PGKWKPKMIGGIGGFVKVKQYDQIPIEICGKKAIGSVLVGPTPANIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135379 LPV 2011 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQILLEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135387 LPV 2012 South Africa B 39 99 PGRWKPKLIGGIGGFVKVRQYDQIPIEICGHKTIGTVLIGPTPANIIGRGLMTQIGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135389 LPV 2012 South Africa C 40 99 GKWKPKMIGGIGGFIKVRQYEQVPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135392 LPV 2012 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYEEIPIEICGKQAIGTVLVGPTPINIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135394 LPV 2010 South Africa C 39 99 PGRWKPKMIGGIGGFIKVRQYDQILVEICGKKAIGTVLVGPTPCNIIGRNLLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135395 LPV 2011 South Africa C 39 99 PGKWKPKIIGGVGGFVRVKQYDHITIEICGKKVKGSVLVGPTPANIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135401 LPV 2009 South Africa C 40 99 GKWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135402 LPV 2009 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135404 LPV 2011 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135405 LPV 2012 South Africa K 39 99 PGKWKPRMIGGIGGFIKVRQYDQVSIEICGKKAIGSVLVGPTPVNIIGRNMLTQIGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135406 LPV 2010 South Africa C 39 99 PGRWRPKIIGGIGGFVKVREYDQVPIEICGKKAIGTVVVGPTPANIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135408 LPV 2012 South Africa C 39 99 PGKWTPKIAGGIGGFVKVKQYEQIPIEICGKKVIGTVLVGPTPINIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135409 LPV 2012 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135412 LPV 2011 South Africa C 39 99 PGKWKPKIIGGIGGFVKVRQYDQIPIEICGKKAIGTVLVGPTPANIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135417 LPV 2012 South Africa C 39 99 PGKWKPKMIGGIGGFIKVKQYEEILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135423 LPV 2012 South Africa C 39 99 PGKWKPKMAGGIGGFIKVRQYDQITIEICGKKAIGTVLVGPTPCNIIGRNLLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135427 LPV 2011 South Africa C 1 99 PQITLWQRPFVSIKVGGQVKEALLDTGADDTVLEEINLPGKWKPKLIGGIGGFVKVRQYDQIPIEICGKKAIGSVLVGPTPANIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135428 LPV 2011 South Africa CRF02_AG 39 99 PGKWKPRMAGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135431 LPV 2011 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQVSIEICGKRAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135433 LPV 2012 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLIGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135436 LPV 2012 South Africa C 40 99 GNWKPKMIGGIGGFIKVRQYDQVHIEICGKKAVGTVLVGPTPINIIGRNILTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135440 LPV 2012 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGSVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135441 LPV 2010 South Africa C 39 99 PGKWKPIMIGGIGGFVKVRQYEDVAIEICGKKAIGTVLVGPTPANIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135442 LPV 2010 South Africa C 39 99 PGKWKPKIIGGIGGFVKVRQYDHIPIEICGKKAIGTVVVGPTPANIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135443 LPV 2012 South Africa CRF02_AG 39 99 PGKWKPKMIGGIGGFVKVRQYDQVAIEICGKKAIGTVLIGPTPANIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135444 LPV 2011 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYEQIIIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135446 LPV 2012 South Africa B 39 99 PGRWKPKMIGGIGGFIKVRQYDQIVIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135447 LPV 2012 South Africa C 39 99 PGKWKPKLIGGIGGFIKVRQYDQIHIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135448 LPV 2012 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQIMIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135449 LPV 2011 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQVPIEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135450 LPV 2010 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135451 LPV 2011 South Africa C 39 99 PGKWKPKIIGGIGGFVRVRQYDQIPIEICGKKVIGTVVVGPTPSNIIGRNLLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135452 LPV 2011 South Africa C 39 99 PGKWKPKMIGGIGGFIKVRQYDQIPIEICGKKAIGTVLVGPTPVNIIGRNLLTQLGCTLNF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2193 135541 LPV 2006 Israel A 4 99 TLWQRPLVTIKIGGQLKEALLDTGADDTVLEDIDLPGRWKPKMIGGIGGFIKVRQYDEIVMEICGKKAIGTVLVGPTPVNIIGRNMLTQIGCTLNF Avidor, B 2013 23469241 PLoS ONE Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy. 2193 135542 LPV 2010 Israel A 4 99 TLWQRPLVTVKIGGQLKEALLDTGADDTVLEDIDLPGKWKPKMIGGIGGFIKVRQYDQILIEICGKKAIGTVLIGPTPVNIIGRNMLTQIGCTLNF Avidor, B 2013 23469241 PLoS ONE Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy.